<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/389148</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;389148</article-id><article-id pub-id-type="other" hwp:sub-type="slug">389148</article-id><article-id pub-id-type="other" hwp:sub-type="tag">389148</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Biochemistry" hwp:journal="biorxiv"><subject>Biochemistry</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Structure-activity relationship of flavin analogs that target the FMN riboswitch</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" fn-type="other" hwp:id="fn-1"><p hwp:id="p-1"><email hwp:id="email-1">quentin.vicens@ucdenver.edu</email>; <email hwp:id="email-2">mondrage@me.com</email>; <email hwp:id="email-3">francis.reyes@thermofisher.com</email>; <email hwp:id="email-4">aristoff@aristoffconsulting.com</email>; <email hwp:id="email-5">philip.coish@yale.edu</email>; <email hwp:id="email-6">juddmberman@gmail.com</email>; <email hwp:id="email-7">hkaur@dalton.com</email>; <email hwp:id="email-8">kwkells@hotmail.com</email>; <email hwp:id="email-9">pcwickens@hotmail.com</email>; <email hwp:id="email-10">jw97ah@yahoo.com</email>; <email hwp:id="email-11">rcgadwood@kalexsyn.com</email>; <email hwp:id="email-12">hjschostarez@kalexsyn.com</email>; <email hwp:id="email-13">robert.suto@xtalbiostructures.com</email>; <email hwp:id="email-14">kblount@rebiotix.com</email>; <email hwp:id="email-15">robert.batey@colorado.edu</email></p></fn><fn id="n2" fn-type="present-address" hwp:id="fn-2" hwp:rev-id="xref-fn-2-1"><label>†</label><p hwp:id="p-2">Department of Biochemistry and Molecular Genetics, RNA BioScience Initiative, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA.</p></fn><fn id="n3" fn-type="present-address" hwp:id="fn-3" hwp:rev-id="xref-fn-3-1"><label>&amp;</label><p hwp:id="p-3">Thermo Fisher Scientific, 5350 NE Dawson Creek Drive, Hillsboro, OR 97124, USA.</p></fn><fn id="n4" fn-type="present-address" hwp:id="fn-4" hwp:rev-id="xref-fn-4-1"><label>∘</label><p hwp:id="p-4">School of Forestry and Environmental Studies, Yale University, 195 Prospect Street, New Haven, CT 06511, USA</p></fn><fn id="n5" fn-type="present-address" hwp:id="fn-5" hwp:rev-id="xref-fn-5-1"><label>$</label><p hwp:id="p-5">Rebiotix, Inc., 2660 Patton Road, Roseville, MN 55113, USA.</p></fn><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1 xref-corresp-1-2"><label>*</label>corresponding authors: <email hwp:id="email-16">quentin.vicens@ucdenver.edu</email>; <email hwp:id="email-17">robert.batey@colorado.edu</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3751-530X</contrib-id><name name-style="western" hwp:sortable="Vicens Quentin"><surname>Vicens</surname><given-names>Quentin</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="fn" rid="n2" hwp:id="xref-fn-2-1" hwp:rel-id="fn-2">†</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0003-3751-530X"/></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Mondragón Estefanía"><surname>Mondragón</surname><given-names>Estefanía</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Reyes Francis E."><surname>Reyes</surname><given-names>Francis E.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref><xref ref-type="fn" rid="n3" hwp:id="xref-fn-3-1" hwp:rel-id="fn-3">&amp;</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Coish Philip"><surname>Coish</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="fn" rid="n4" hwp:id="xref-fn-4-1" hwp:rel-id="fn-4">∘</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Berman Paul Aristoff Judd"><surname>Berman</surname><given-names>Paul Aristoff Judd</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Kaur Harpreet"><surname>Kaur</surname><given-names>Harpreet</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Kells Kevin W."><surname>Kells</surname><given-names>Kevin W.</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-3" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Wickens Phil"><surname>Wickens</surname><given-names>Phil</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-4" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Wilson Jeffery"><surname>Wilson</surname><given-names>Jeffery</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-5" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Gadwood Robert C."><surname>Gadwood</surname><given-names>Robert C.</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-11"><name name-style="western" hwp:sortable="Schostarez Heinrich J."><surname>Schostarez</surname><given-names>Heinrich J.</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-2" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-12"><name name-style="western" hwp:sortable="Suto Robert K."><surname>Suto</surname><given-names>Robert K.</given-names></name><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-13"><name name-style="western" hwp:sortable="Blount Kenneth F."><surname>Blount</surname><given-names>Kenneth F.</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="fn" rid="n5" hwp:id="xref-fn-5-1" hwp:rel-id="fn-5">$</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-14"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1384-6625</contrib-id><name name-style="western" hwp:sortable="Batey Robert T."><surname>Batey</surname><given-names>Robert T.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-2" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-1384-6625"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4"><label>1</label><institution hwp:id="institution-1">Department of Chemistry and Biochemistry, University of Colorado</institution>, 596 UCB, Boulder, CO 80309, <country>USA</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2"><label>2</label><institution hwp:id="institution-2">BioRelix</institution> Inc., 124 Washington St, Foxborough, MA 02035, <country>USA</country></aff><aff id="a3" hwp:id="aff-3"><label>3</label><institution hwp:id="institution-3">Aristoff Consulting LLC</institution>, 3726 Green Spring Drive, Fort Collins, CO 80528, <country>USA</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2 xref-aff-4-3 xref-aff-4-4 xref-aff-4-5"><label>4</label><institution hwp:id="institution-4">Dalton Pharma Services</institution>, 349 Wildcat Rd., Toronto, ON M3J 2S3, <country>Canada</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1 xref-aff-5-2"><label>5</label><institution hwp:id="institution-5">Kalexsyn</institution>, Inc., 4502 Campus Dr., Kalamazoo, MI 49008, <country>USA</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">Xtal BioStructures</institution>, Inc., 12 Michigan Dr., Natick, MA 01760, <country>USA</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-08-09T23:39:21-07:00">
    <day>9</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-08-09T23:39:21-07:00">
    <day>9</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-08-09T23:45:54-07:00">
    <day>9</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-08-09T23:45:54-07:00">
    <day>9</day><month>8</month><year>2018</year>
  </pub-date><elocation-id>389148</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-08-09"><day>09</day><month>8</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-08-09"><day>09</day><month>8</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-08-09"><day>09</day><month>8</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license hwp:id="license-1"><p hwp:id="p-6">The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</p></license></permissions><self-uri xlink:href="389148.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/389148v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="389148.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/389148v1/389148v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/389148v1/389148v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">ABSTRACT</title><p hwp:id="p-7">The flavin mononucleotide (FMN) riboswitch is an emerging target for the development of novel RNA-targeting antibiotics. We previously discovered an FMN derivative —5FDQD— that protects mice against diarrhea-causing <italic toggle="yes">Clostridium difficile</italic> bacteria. Here, we present the structure-based drug design strategy that led to the discovery of this fluoro-phenyl derivative with antibacterial properties. This approach involved the following stages: (1) structural analysis of all available free and bound FMN riboswitch structures; (2) design, synthesis and purification of derivatives; (3) <italic toggle="yes">in vitro</italic> testing for productive binding using two chemical probing methods; (4) <italic toggle="yes">in vitro</italic> transcription termination assays; (5) resolution of the crystal structures of the FMN riboswitch in complex with the most mature candidates. In the process, we delineated principles for productive binding to this riboswitch, thereby demonstrating the effectiveness of a coordinated structure-guided approach to designing drugs against RNA.</p><sec hwp:id="sec-1"><title hwp:id="title-2">GRAPHICAL ABSTRACT</title><fig id="ufig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/UFIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">ufig1</object-id><caption hwp:id="caption-1"><title hwp:id="title-3">Exploring the chemical structure landscape of FMN riboswitch binders.</title></caption><graphic xlink:href="389148_ufig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig></sec></abstract><counts><page-count count="37"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-2"><title hwp:id="title-4">INTRODUCTION</title><p hwp:id="p-8">Since seminal work on antibiotic-RNA complexes in the 1980s-90s, RNA has been recognized as a promising therapeutic target for small molecules.<sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>–<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref></sup> At least half of the known families of antibiotics target ribosomal RNA, including linezolid, one of the most recently discovered antibiotics.<sup><xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref></sup> Since the year 2000, three-dimensional structures of ribosome-antibiotic complexes solved using X-ray crystallography and cryo-electron microscopy have helped us decipher drug-RNA binding principles.<sup><xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref></sup> Today, many companies —including pharmaceutical giants like Merck, Pfizer, and Novartis— are running programs aimed at targeting RNA with small molecules.<sup><xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>–<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref></sup></p><p hwp:id="p-9">Biosensors mostly found in bacteria and called “riboswitches” were recognized soon after their discovery as promising RNA drug targets, mostly because they consist of structured RNA elements that regulate the expression of genes essential for survival/virulence of some medically important pathogens through the binding of small molecules or ions.<sup><xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>–<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref></sup> Disrupting molecular switches is a proven strategy for achieving inhibitory bioactivity,<sup><xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref></sup> including documented examples of riboswitches that can productively bind natural products and anti-metabolites. For example, sinefungin binds to the S-adenosyl methionine (SAM) riboswitch,<sup><xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref></sup> antifolates can regulate the tetrahydrofolate riboswitch,<sup><xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref></sup> and the <italic toggle="yes">thi</italic>-box riboswitch was crystallized in the presence of a variety of thiamine pyrophosphate analogs.<sup><xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref></sup> However, analog binding is not synonymous with antimicrobial action <italic toggle="yes">in vivo</italic>. For instance, although lysine analogs bind to the lysine riboswitch,<sup><xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref></sup> their antibacterial activity actually mostly stems from their incorporation into nascent proteins.<sup><xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref></sup> Notably, a case where binding of a compound has an antimicrobial effect is illustrated by roseoflavin (RoF) —produced by <italic toggle="yes">Streptomyces davawensis</italic>—<sup><xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref></sup>, whose antibacterial action comes from binding of its phosphorylated form (RoFMN) to the flavin mononucleotide (FMN) riboswitch.<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref></sup> RoFMN binding downregulates the expression of downstream genes,<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-2" hwp:rel-id="ref-17">17</xref></sup> which offers a compelling evidence that riboswitches are generally valid targets for drug design efforts.<sup><xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref></sup></p><p hwp:id="p-10">For structure-guided design of novel riboswitch-targeting compounds, the three-dimensional architecture of the complex between the riboswitch and its natural cognate ligand is the starting point for exploring chemical space through optimizing the pharmaceutical properties of the ligand.<sup><xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>–<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref></sup> For example, this strategy was used to design purine analogs that had antimicrobial action by binding to the purine riboswitch.<sup><xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">19</xref></sup> Additional structure-function characterizations guided the design of modified pyrimidines that could also be accommodated in the binding pocket of the purine riboswitch, in order to interfere with gene expression.<sup><xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>, <xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref></sup> These successful efforts illustrate that reaching ligand-specific pharmacochemical goals leads to superior therapeutic compounds.</p><p hwp:id="p-11">A key aspect of structure-guided design approaches is that they do not solely rely on visualizing ligand-bound states, but also on interrogating the ensemble of unbound states, using techniques such as in-line probing,<sup><xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref></sup> Selective 2’ Hydroxyl Acylation analyzed by Primer Extension (SHAPE),<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref></sup> small angle X-ray scattering,<sup><xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref></sup> fluorescence,<sup><xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref></sup> NMR,<sup><xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref></sup> and most recently X-ray free electron laser.<sup><xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref></sup> Precisely mapping local conformational changes associated with ligand binding is in fact critical for identifying ligand positions that can be modified, while maintaining activity. The bioactivity of the resulting compounds is in turn tested using the same techniques. In the case of the purine, SAM, and FMN riboswitches, these methods suggested that ligand recognition occurs by conformational selection of a preformed structure, rather than through a more extensive allosteric mechanism.<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-2" hwp:rel-id="ref-24">24</xref>–<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-2" hwp:rel-id="ref-25">25</xref>, <xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>–<xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref></sup> Structure-guided drug design is particularly promising in such scenarios, because the architecture of the active site as seen in the bound structure is similar to that encountered by a ligand upon binding.</p><p hwp:id="p-12">Herein, we present the main pathways of a medicinal chemistry strategy for optimizing RoFMN that led to the discovery of 5FDQD (5-(3-(4-fluorophenyl)butyl)-7,8-dimethylpyrido[3,4-b]-quinoxaline-1,3(2H,5H)-dione; <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 1A</xref>), a synthetic fluoro-phenyl analog of RoFMN that binds to the FMN riboswitch of <italic toggle="yes">Clostridium difficile</italic>. Importantly, 5FDQD was shown to be bactericidal toward <italic toggle="yes">C. difficile</italic> without perturbing the host mouse microbiome.<sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref></sup> Furthermore, the frequency of developing resistance against 5FDQD is low (&lt; 1 x 10<sup>-9</sup>) <sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-2" hwp:rel-id="ref-31">31</xref></sup>. Using a combination of chemical probing techniques and transcription termination assays, we characterized the contribution to RNA binding and regulatory activity of various FMN and RoFMN synthetic analogs. The structures of three of the most promising compounds were determined using X-ray crystallography. In addition, we performed a meta-analysis of known ligands that target the FMN riboswitch,<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-2" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>–<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref></sup> including Merck’s ribocil, an unnatural ligand with a novel chemical scaffold<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-2" hwp:rel-id="ref-32">32</xref></sup>. Principles for designing effective drugs could be derived, so that bioavailability, binding to this riboswitch, and efficiency are not compromised. Overall, this work further establishes the FMN riboswitch as a powerful model system for understanding how to target RNA.</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5 xref-fig-2-6 xref-fig-2-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1</label><caption hwp:id="caption-2"><title hwp:id="title-5">Roseoflavin mononucleotide at the center of a medicinal chemistry optimization strategy that led to the discovery of synthetic analogs with potent activity and selectivity.</title><p hwp:id="p-13">(A) Chemical structure of 5FDQD (5-(3-(4-fluorophenyl)butyl)-7,8-dimethylpyrido[3,4-b]-quinoxaline-1,3(2H,5H)-dione), a potent inhibitor of the FMN riboswitch. Color-coding for functional groups introduced during SAR study: orange, negatively charged/polar group; tan, hydrophobic group. IC<sub>50</sub>, half maximal inhibitory concentration as measured by in-line probing; EC<sub>50</sub>, half maximal effective concentration in transcription termination assays.<sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-3" hwp:rel-id="ref-31">31</xref></sup> Note that all values for IC<sub>50</sub> and EC<sub>50</sub> in subsequent figures are given in units of μM. (B) Secondary structure of the FMN riboswitch showing sequence and structure conservation among bacteria. Residues that interact with flavin-bearing ligands in crystal structures are circled in pink.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-3" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-2" hwp:rel-id="ref-33">33</xref></sup> The list of the six joining regions is indicated, with numbering for <italic toggle="yes">B. subtilis</italic> and <italic toggle="yes">F. nucleatum</italic> (in parenthesis). (C) Dissecting functional positions 8 and 10 of roseoflavin mononucleotide (RoFMN) over the course of a structure-activity relationship (SAR) study of the FMN riboswitch. Color-coding for functional groups: red, left unaltered during SAR study; green, primary focus of SAR study; blue, secondary focus. IC<sub>50</sub> and EC<sub>50</sub> calculated as for 5FDQD (see Methods; Tables S1 and S2; Figure S1). (D) Comparative banding pattern of SHAPE chemical probing within the J6/1 joining region, which serves as an indicator for ligand binding.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-4" hwp:rel-id="ref-30">30</xref></sup> [MgCl<sub>2</sub>] tested were: 0, 0.1, 0.5, 2.0 and 15.0 mM. Arrowheads: residues of interest within J6/1. The gels were aligned in SAFA<sup><xref ref-type="bibr" rid="c55" hwp:id="xref-ref-55-1" hwp:rel-id="ref-55">55</xref>–<xref ref-type="bibr" rid="c56" hwp:id="xref-ref-56-1" hwp:rel-id="ref-56">56</xref></sup> (full unaltered SHAPE gels shown in Figure S2).</p></caption><graphic xlink:href="389148_fig1" position="float" orientation="portrait" hwp:id="graphic-2"/></fig></sec><sec id="s2" hwp:id="sec-3"><title hwp:id="title-6">RESULTS AND DISCUSSION</title><sec id="s2a" hwp:id="sec-4"><title hwp:id="title-7">Design rationale</title><p hwp:id="p-14">Our rationale for optimizing RoFMN stemmed from the following challenges. First, until after this project was completed,<sup><xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>–<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref></sup> roseoflavin was thought to enter bacteria only via an active riboflavin transporter specific to Gram-positive bacteria.<sup><xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>–<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref></sup> This could limit intracellular concentrations of roseoflavin, thereby restricting its potency and activity spectrum. In addition, since these riboflavin transporters are not essential, their mutation could render bacteria resistant to roseoflavin. Second, roseoflavin requires intracellular phosphorylation to exert antibacterial activity as RoFMN,<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-3" hwp:rel-id="ref-17">17</xref></sup> as suggested by in-line probing and fluorescence-based assays that demonstrated a ~1,000-fold decrease in binding affinity when the phosphate group is removed.<sup><xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">23</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-3" hwp:rel-id="ref-33">33</xref></sup> The requirement for phosphorylation also constitutes another avenue for resistance to emerge. Moreover, RoFMN antibacterial activity could be self-limiting, if growth inhibition decreases the effectiveness of roseoflavin phosphorylation. Third, the need for roseoflavin to be recognized and activated by multiple proteins required for its transport and phosphorylation imposes additional structural and functional constraints on the ligand. Finally, roseoflavin is rapidly cleared from plasma (K.F.B., unpublished results). Given these challenges, our pharmacochemical goals were to identify RoFMN analogs that could be passively transported into bacteria and not require phosphorylation to be active.</p><p hwp:id="p-15">The first optimization stage was to examine the interaction of FMN and roseoflavin with FMN riboswitches for key recognition motifs and behaviors that new analogs would need to maintain or replace.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-5" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-4" hwp:rel-id="ref-33">33</xref></sup> Four elements seemed important: [1] a pseudo-base pair involving A99 and the uracil-like face of the isoalloxazine ring system; [2] a metal ion-mediated interaction involving the FMN phosphate and four of the six joining regions; [3] aromatic stacking between A48 (within joining (J) regions J3/4), the isoalloxazine moiety, and A85 (adjacent to J5/6); and [4] four of the six joining regions interacting with the ligand in crystal structures<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-6" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-5" hwp:rel-id="ref-33">33</xref></sup> (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 1B</xref>) undergo significant conformational change upon binding, two of which maintain a structure of the binding pocket that is conducive to ligand binding: J4/5 (which through G62 is part of a metal-mediated interaction involving the phosphate group at position 10 of FMN), and J3/4 (which through A48 is in the vicinity of U61 and position C8 of FMN, a natural site for derivatization (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 1C</xref>)<sup><xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref></sup>).<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-7" hwp:rel-id="ref-30">30</xref></sup> Furthermore, the hydroxyl groups of the ribityl-phosphate chain at position 10 of the isoalloxazine ring system do not contact RNA and their contribution to binding is minimal.<sup><xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-3" hwp:rel-id="ref-23">23</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-6" hwp:rel-id="ref-33">33</xref></sup> Hence, although the ribityl group forms a hydrogen bond to O6 of G11, it appears to merely direct a negatively charged group to a critical location. Its hydroxyl groups could likely be removed without altering activity, while potentially significantly improving passive membrane permeation. From these observations, it was concluded that positions 8 and 10 on the isoalloxazine ring system would be the most promising in the search for synthetic flavin analogs that bypass phosphorylation requirements.</p></sec><sec id="s2b" hwp:id="sec-5"><title hwp:id="title-8">Step-by-step breakdown of the ribityl group off position 10 on the flavin heterocycle</title><p hwp:id="p-16">To assess whether hydroxyl groups on the ribityl chain at position N10 of the isoalloxazine heterocycle were dispensable, we carried out a systematic dissection of the contributions of each chemical element at that position. To that end, compounds were purchased or synthesized (see SI Methods) that progressively stripped functional groups off the N10 chain (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 1C</xref>). BRX247 and BRX830 were the endpoints of this series, in which all hydroxyl groups on the ribose were removed to yield an alkyl chain. In BRX247, the terminal phosphate group was removed.</p><p hwp:id="p-17">We comparatively assessed the effect of these compounds on the structure and the activity of the <italic toggle="yes">Bacillus subtilis ribD</italic> FMN riboswitch (Figure S1A) bound to these derivatives using inline probing,<sup><xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-4" hwp:rel-id="ref-23">23</xref>, <xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref></sup> SHAPE, <sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-8" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref></sup> and transcription termination assays.<sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-4" hwp:rel-id="ref-31">31</xref></sup> FMN, roseoflavin, and lumiflavin were used as controls.<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-4" hwp:rel-id="ref-17">17</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-5" hwp:rel-id="ref-23">23</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-7" hwp:rel-id="ref-33">33</xref></sup> These data largely recapitulated earlier findings on the relative importance of the ribityl and phosphate groups, in support of RoFMN being the active form of roseoflavin in cells.<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-5" hwp:rel-id="ref-17">17</xref></sup> In addition, we showed that an alkyl chain could substitute for the ribityl chain (compare FMN and BRX830; <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Figure 1C</xref>). Further, SHAPE analysis revealed that BRX830, but not BRX247, promoted structural changes in the binding pocket similar to that of RoFMN, suggestive of productive binding to the riboswitch (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-6" hwp:rel-id="F2">Figure 1D</xref>). This observation confirmed the need for a negatively charged group to organize the binding core of the RNA, while also encouraging the design of alternatives to the ribityl chain and potentially the phosphate group at its end.</p></sec><sec id="s2c" hwp:id="sec-6"><title hwp:id="title-9">Synthetic ligands with superior potency to roseoflavin mononucleotide</title><p hwp:id="p-18">With the next series of compounds, we explored whether the phosphate group could be functionally replaced by a less labile negatively charged group. When the phosphate group of BRX830 was replaced by a carboxylic group (leading to the heptanoic acid side chain at position 10 in BRX857; <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 2A</xref>), a 100-fold decrease in IC<sub>50</sub>, and a 6-fold loss in EC<sub>50</sub> were observed. Shortening the alkyl chain as in BRX897 (from 6 to 4 carbon atoms, leading to a pentanoic acid side chain; <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 2A</xref>) resulted in slightly lower binding affinity, and a further 10-fold reduction in activity. However, the riboswitch was tolerant of various chain lengths within a 5–7 carbon-atom range (affinities varied between 0.2-0.9 μM; EC<sub>50</sub> for 4–7 carbon atoms were ranked as follows: C6 &gt; C5 ≫ C4,C7; data not shown). Both BRX857 and BRX897 partially induced a roseoflavin-like conformational changes at the binding site, as indicated by SHAPE (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 2B</xref>). Notably, removing the <italic toggle="yes">N</italic>-dimethyl group at position 8 led to a 10-fold improvement in affinity and a four-fold improvement in activity (compare BRX1027 to BRX857; <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Figure 2A</xref>). Other replacements of the phosphate group were less effective for binding than carboxylic acid (e.g., IC<sub>50</sub> (nitrile) ~ 4.5 μM; data not shown). Interestingly, moving the heptanoic acid chain from position N10 to positions N1 or C9 on the isoalloxazine heterocycle led to compounds that showed improved permeability as tested using a parallel artificial membrane permeability assay,<sup><xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref></sup> but weaker functional activity (for BRX1027, permeability index (pe) = 0.87; for heptanoic acid at N1: IC<sub>50</sub> = 0.7 μM, EC<sub>50</sub> = 8 μM, pe = 8.4; for heptanoic acid at C9: IC<sub>50</sub> = 0.33 μM, EC<sub>50</sub> = 1.7 μM, pe = 5.4; data not shown). In summary, BRX1027 displayed physicochemical properties superior to those of the natural ligands, but its effectiveness in promoting transcription termination was weak. BRX1027 thus provided a novel structural framework, where potential functionalization sites could be incorporated both at positions 8 and within the heptanoic acid chain.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4 xref-fig-3-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2</label><caption hwp:id="caption-3"><title hwp:id="title-10">Drug leads in which the phosphate group was replaced by a carboxylic acid.</title><p hwp:id="p-19">(A) A carboxylic group in place of the phosphate group only results in a minor drop in binding and activity. Color-coding for functional groups: green, as in Figure 1; orange, negatively charged/polar group introduced during SAR study (raw and normalized data in Tables S1 and S2; Figure S1). (B) Banding pattern of SHAPE chemical probing within the J6/1 joining region for compounds shown in panel (A), as in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-2-7" hwp:rel-id="F2">Figure 1</xref> (full unaltered SHAPE gels shown in Figure S2).</p></caption><graphic xlink:href="389148_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-20">The next aspect of this SAR study examined the effect of adding hydrophobic and heterocyclic groups at positions 8 and 10 of the isoalloxazine ring system in BRX1027. Such ring systems make for trademarks of successful designer drugs.<sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-2" hwp:rel-id="ref-1">1</xref>, <xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>–<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref></sup> For example, adding a cyclopentyl ring at the N8 position of BRX857 (as in BRX1151) partially restored high affinity binding while improving transcription termination by a factor of 10 (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 3A</xref>). Also, although the introduction of an amine within the heptanoic acid chain leads to a decrease in affinity and activity (BRX931; <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Figure 3A</xref>), it opened the possibility of introducing various functionalizations, such as a piperidine (as in BRX1224; <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-3" hwp:rel-id="F4">Figure 3A</xref>). Going from BRX931 to BRX1224, binding affinity had improved by 26-fold and activity by 225-fold (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-4" hwp:rel-id="F4">Figure 3A</xref>). These effects were not necessarily additive though, as demonstrated by BRX1072, which had a lower affinity than BRX1151 and BRX1224, despite possessing both a piperidine as in BRX1224 and a cyclopropyl at position 8 (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-5" hwp:rel-id="F4">Figure 3A</xref>). BRX1151 but also to some extent BRX1072 and BRX1224 were successful at promoting FMN-like conformational changes of the binding site (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-6" hwp:rel-id="F4">Figure 3B</xref>), which encouraged us to solve the structure of BRX1151 bound to the riboswitch (see below).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3 xref-fig-4-4 xref-fig-4-5 xref-fig-4-6 xref-fig-4-7 xref-fig-4-8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3</label><caption hwp:id="caption-4"><title hwp:id="title-11">Developing mature drug leads by adding hydrophobic groups and heteroatoms.</title><p hwp:id="p-21">(A) Hydrophobic groups and heterocycles at positions 8 and/or 10 restore partial binding and efficacy. Color-coding for functional groups: orange, same as above; tan, hydrophobic. (B) SHAPE banding pattern for BRX1151 and BRX1072. (C) Ligands with aromatic side chains off position 8. (D) Plot of the average of the normalized fraction of RNA cleaved at G136 versus FMN/BRX1555 concentration. Curves indicate the best fit of the data to an equation for a two-state binding model (raw data shown in Figure S1). (E) Polyacrylamide gel analysis of a transcription termination assay using BRX1151, BRX1555 and FMN (left). Plot depicting the fraction of transcripts in the terminated form versus ligand concentration (right). Curves indicate the best fit of the data to a two-state model for ligand-dependent termination activity (raw and normalized data in Tables S1 and S2; Figure S1; full unaltered SHAPE gel shown in Figure S2).</p></caption><graphic xlink:href="389148_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><p hwp:id="p-22">At that point, BRX1151 was the most attractive candidate to emerge from our study, with IC<sub>50</sub> and EC50 values that were sufficiently low to warrant bioactivity. Yet, although less labile than a phosphate group <italic toggle="yes">in vivo</italic>, a negatively charged carboxylic group still depends on a transporter to cross bacterial membranes, representing a major limitation to bioavailability. Thus, BRX1151 merely served as a proof of principle that the phosphate group responsible for the activity of (Ro)FMN and BRX830 could be replaced by another negatively charged group. To generate a derivative that would be effective as a drug, we further explored the derivatization of BRX1151 to bypass the need for a negatively charged functional group.</p></sec><sec id="s2d" hwp:id="sec-7"><title hwp:id="title-12">Aromatic hydrocarbons to the rescue: the discovery of BRX1555</title><p hwp:id="p-23">To circumvent critical issues of having a derivative with a carboxylic group, an approach consisting in introducing hydrophobic groups proved most rewarding. Adding a phenyl moiety to BRX931 through an amine inserted in the alkyl chain led to a recovery in binding affinity of the same order of magnitude as that seen in the compounds with cyclopentyl or piperidine, i.e. only about 2-3 times weaker than FMN (BRX1354; <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-7" hwp:rel-id="F4">Figure 3C</xref>). This addition also had the effect of restoring transcription termination inhibition to the level of FMN. Bypassing the carboxylic group but maintaining an aromatic group at the end of the alkyl chain resulted in BRX1555, a compound with a binding affinity of 39 nM, and an EC<sub>50</sub> of 1.7 μM (similar to that of BRX857; <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-3-5" hwp:rel-id="F3">Figures 2</xref> and <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-4-8" hwp:rel-id="F4">3C, D</xref>). Increasing the length of the alkyl chain in BRX1555 by one carbon atom decreased transcription termination efficiency by a factor of 10 (data not shown). Other alternatives to the carboxylic group combining heteroatoms and aromatic rings were less effective (e.g., EC<sub>50</sub> (-pentyl thiazolidinedione) = 5.1 μM; EC<sub>50</sub> (-piperidinyl acyl sulfonamide) = 23 μM; data not shown). Worthy of note, tert-butyl and phenethyl carboxylate derivatives that could be used as prodrugs consistently displayed weak activity in microbiology assays (e.g., MIC ≤ 16 μg/mL against <italic toggle="yes">Staphylococcus aureus</italic> NRS384), but were unstable (plasma levels of 7.6 μg/mL (tertbutyl), 0.08 μg/mL (phenylethyl), and under quantifiable limits (tertbutyl with C8-chloro substitution), as measured 5 min after administering a 5 mg/kg IV dose to rodents; data not shown).</p><p hwp:id="p-24">Fortunately, the promising IC<sub>50</sub> and EC<sub>50</sub> values of BRX1555 were accompanied by a weak but consistent activity against several strains of <italic toggle="yes">Staphylococcus aureus</italic> (laboratory strain RN4220; Rosenbach, ATCC #29213; multi-resistant NRS384) and <italic toggle="yes">Streptococcus pneumoniae</italic> (Chester, ATCC #49619; Table S3; data not shown). Further modifications of BRX1555 at position 8 (e.g., removal of the methyl group, chloro substitution, addition of propylene glycol to N8) led to compounds with improved solubility, cytotoxicity, but not potency (Table S3; data not shown). Subsequent efforts exploring the BRX1555 scaffold led to the identification of 5FDQD —originally called BRX2102— which retained the BRX1555 skeleton with the addition of a methyl group on the alkyl chain and a fluorine substituent on the phenyl moiety.</p></sec><sec id="s2e" hwp:id="sec-8"><title hwp:id="title-13">Substituents at positions 8 and 10 confer selectivity for certain bacterial strains</title><p hwp:id="p-25">While exploring the effect on binding of adding substituents at position 8, we noticed an effect on selectivity. For example, BRX1027 was compared to BRX1070 (similar to BRX1027 but possessing a cyclopropyl substituent at position N8; <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 4A</xref>) for binding to the FMN riboswitch from four bacterial strains, including <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Staphylococcus epidermidis,</italic> using in-line probing assays. Both <italic toggle="yes">S. aureus ypaA</italic> and <italic toggle="yes">S. epidermidis</italic> were sensitive to a different extent to RoFMN (MIC<sub>50</sub> (<italic toggle="yes">S. aureus</italic>) = 8 μg/mL; MIC<sub>50</sub> <italic toggle="yes">(S. epidermidis)</italic> = 32 μg/mL; data not shown). The results of this comparative analysis were that although FMN and BRX1070 would bind similarly to all tested riboswitches, BRX1027 would not (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 4B</xref>). The affinity of BRX1027 for the <italic toggle="yes">S. aureus</italic> riboswitches was ~10-fold lower than that to <italic toggle="yes">B. subtilis</italic>, and ~20-fold lower to <italic toggle="yes">S. epidermidis</italic> (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Figure 4B</xref>). A 35-fold decrease in affinity was also noticed for a halogenated derivative of BRX1555 (i.e., BRK1675; <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figure 4A</xref>) between <italic toggle="yes">B. subtilis</italic> and a <italic toggle="yes">C. difficile-specific</italic> FMN riboswitch (i.e., CD3299; <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Figure 4B</xref>).<sup><xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref></sup> Similarly, SHAPE mapping revealed poor binding of BRX1027 to the <italic toggle="yes">Fusobacterium nucleatum</italic> FMN riboswitch, in comparison to FMN, BRX857 and BRX1151 (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Figure 4C</xref>). Together, these observations suggested that to target a specific strain, a substituent would need to be present at position 8 when a carboxylic acid is at position 10. Interestingly, in the context of BRX1555 (Table S3), BRX1675 (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-5-7" hwp:rel-id="F5">Figure 4</xref>) and 5FDQD,<sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-5" hwp:rel-id="ref-31">31</xref></sup> selectivity was achieved in absence of a substituent at position 8, emphasizing the interplay between the nature of a substituent at position 8, and that at position 10.</p><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6 xref-fig-5-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4</label><caption hwp:id="caption-5"><title hwp:id="title-14">Selectivity of flavin analogs.</title><p hwp:id="p-26">(A) Chemical structures of BRX1070 and BRX1675. (B) IC<sub>50</sub> values (μM) from in-line probing assays using FMN, three BRX compounds, and five different riboswitch sequences. (C) Mg<sup>2+</sup>-dependent probing of the <italic toggle="yes">F. nucleatum</italic> riboswitch with a series of BRX compounds. Residues 100 and 103 within the J6/1 joining region are marked by arrows (full unaltered SHAPE gel shown in Figure S2).</p></caption><graphic xlink:href="389148_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><p hwp:id="p-27">In order to gain selectivity for a particular flavin-based drug, the sequence of J4/5 (residues 61–63 in <italic toggle="yes">F. nucleatum</italic>) may need to be taken into account, as J4/5 differentially interacts with position 8 and position 10 substituents depending on the ligand (see next section). While the sequence of J4/5 is UGGA in <italic toggle="yes">B. subtilis</italic>, it is UGA in <italic toggle="yes">F. nucleatum</italic>, CUGA in the two <italic toggle="yes">Staphylococcus</italic> strains, and UUGA in <italic toggle="yes">C. difficile</italic>. Although this interplay in species selectivity had not been reported, it is compatible with earlier findings.<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-6" hwp:rel-id="ref-17">17</xref></sup> For example, binding characteristics are similar whether roseoflavin binds to the FMN riboswitch from <italic toggle="yes">B. subtilis</italic> or from <italic toggle="yes">S. davawensis</italic> (J4/5 is UUGA), although it was proposed that the phosphorylated form of roseoflavin discriminates between the two species in a manner different from FMN.<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-7" hwp:rel-id="ref-17">17</xref></sup> It is the combination of such observations about affinity, <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> activity, as well as selectivity, that eventually led to the design of 5FDQD, which is selectively active against <italic toggle="yes">C. difficile</italic> in the mouse gut.</p></sec><sec id="s2f" hwp:id="sec-9"><title hwp:id="title-15">Distinct ligand-RNA interactions support a conserved architecture of the binding site</title><p hwp:id="p-28">To gain insights into how functional groups added at positions 8 and 10 were accommodated in the binding site of the FMN riboswitch, we solved the crystal structures of BRX1151, BRX1354 and BRX1555 bound to the aptamer domain of the FMN riboswitch from <italic toggle="yes">F. nucleatum</italic>, using previously published strategies.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-9" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-8" hwp:rel-id="ref-33">33</xref></sup> The overall RNA folds were similar for the three ligands and they supported a similar architecture of the binding site (Figure S3A). In all complexes, the isoalloxazine ring system intercalates between A48 and the G98-A85 pair, and the uridine-like moiety forms a pseudo-Watson-Crick base pair with A99, as in the FMN complex (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 5A–D</xref>; Figure S3B–D). Local structural differences occurred for the backbone atoms at J4/5, as previously reported for various ligands bound to the riboswitch (Figure S3A).<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-10" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-9" hwp:rel-id="ref-33">33</xref></sup> In short, crystal structures confirmed the structural similarity that was suggested by in-line probing and SHAPE data.</p><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3 xref-fig-6-4 xref-fig-6-5 xref-fig-6-6 xref-fig-6-7 xref-fig-6-8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5</label><caption hwp:id="caption-6"><title hwp:id="title-16">Visualizing how different chemical scaffolds promote binding to the FMN riboswitch.</title><p hwp:id="p-29">(A) Organization of the binding site in absence of ligand (PDB ID 2YIF) and in presence of FMN (PDB ID 2YIE).<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-11" hwp:rel-id="ref-30">30</xref></sup> (B) Close-up on J1/2 and J4/5. (C) 2F<sub>o</sub>-F<sub>c</sub> maps of three roseoflavin analogs (map contour: 1.0 σ), showing intercalation of the isoalloxazine moiety and its pseudo-Watson-Crick pairing with A99. J1/2 and J2/3 are omitted for clarity. (D) Plasticity of interaction types in the region involving J1/2 and J4/5. (E) Same view as in (A, C) for the FMN-riboswitch bound to ribocil (PDB ID 5C45).<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-3" hwp:rel-id="ref-32">32</xref></sup> (F) Same view as in (B, D) for the ribocil-bound riboswitch.</p></caption><graphic xlink:href="389148_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><p hwp:id="p-30">An unexpected aspect of these structures is how the various modifications are accommodated in the binding pocket. The carboxylic group at the end of the alkyl chain (in BRX1151 and BRX1354) interacts with G62 in a similar manner to the phosphate group at the end of the ribose chain in FMN (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 5C, D</xref>). G62 had been identified as one of the four guanosines that interact with the phosphate group of FMN and a magnesium ion in the co-crystal structure,<sup><xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-10" hwp:rel-id="ref-33">33</xref></sup> as well as belonging to one of the two joining regions (J3/4 and J4/5) that undergo conformational change upon binding.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-12" hwp:rel-id="ref-30">30</xref></sup> No metal ion was detected though in the case of the BRX complexes, suggesting a magnesium ion is dispensable for binding efficiency, at least in the absence of a phosphate group. In BRX1555, which does not contain any negative charge, the phenyl moiety at the end of the alkyl chain is stacked against G62 (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 5C, D</xref>). Within that structure, a strong density peak between G62 and G11 was best modeled as a chloride ion, consistent with the presence of a negative charge in that area in the other complexes (Figure S5E). However, further experiments would be needed to confirm the nature of the putative chloride ion. Also, the presence of the substituted —and likely protonated— amino group at position 8 of the isoalloxazine system in BRX1151 results in a hydrogen bond to the 2’-OH of U61 from J4/5 (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-4" hwp:rel-id="F6">Figure 5C</xref>). Finally, the phenyl moieties that were added to BRX1354 and BRX1555 adopt different orientations: in BRX1354 the ring stacks against the isoalloxazine moiety while in BRX1555 it stacks against G62 (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-5" hwp:rel-id="F6">Figure 5C, D</xref>). This variability in tolerating a similar functional group is not what we would have predicted from the chemical structures.</p><p hwp:id="p-31">Overall, this select structural analysis of some of the most mature BRX compounds illustrated how the FMN riboswitch can adjust to recognizing ligands with a variety of functional groups, consistent with the flexibility reported by SHAPE for U61/G62 (J4/5) and G10/G11 (J1/2) in the free state ensemble.<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-13" hwp:rel-id="ref-30">30</xref></sup> What these new structures further illustrate is that in addition to stacking against A48 (J3/4) and interacting with A99 (J6/1), some form of interaction with G62 is critical for productive binding (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-6" hwp:rel-id="F6">Figure 5A–D</xref>). Interestingly, the structure of ribocil, a compound identified in high-throughput screening supports that conclusion as well.<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-4" hwp:rel-id="ref-32">32</xref></sup> Although its chemical structure is distinct from FMN relatives, its pattern of interactions within the binding pocket follows similar rules (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-7" hwp:rel-id="F6">Figure 5E, F</xref>). In particular, the 2-methylaminopyrimidine moiety of ribocil stacks against G62 in the crystal structure, in a manner that is consistent with what we observe for the phenyl ring of BRX1555 (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-6-8" hwp:rel-id="F6">Figure 5C, F</xref>). Further highlighting the critical role of the interaction between G62 and a ligand, it was proposed that disruption of this interaction was responsible for loss of FMN and ribocil binding in a riboswitch mutant in which G62 and adjacent residues had been deleted.<sup><xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref></sup></p></sec><sec id="s2g" hwp:id="sec-10"><title hwp:id="title-17">Making a case for integrated medicinal chemistry strategies</title><p hwp:id="p-32">The discovery of 5FDQD exemplifies how an effective and selective drug can be designed by leveraging biochemical, functional and structural data about an RNA target.<sup><xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-6" hwp:rel-id="ref-31">31</xref></sup> In this process, a key is to reach a confluence between the positions of a drug lead that appear modifiable according to available biochemical and structural data, and the elements that seem to limit effectiveness in the eyes of medicinal chemists. The FMN riboswitch is currently one of the few RNAs—together for example with the ribosomal decoding site<sup><xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>–<xref ref-type="bibr" rid="c49" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref></sup>—for which natural antibacterials (e.g. roseoflavin),<sup><xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-8" hwp:rel-id="ref-17">17</xref></sup> synthetic compounds (5FDQD and this work) and entirely new scaffolds (ribocil<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-5" hwp:rel-id="ref-32">32</xref></sup>, WG-3<sup><xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref></sup>) have been extensively studied, making it a particularly attractive system for improving our ability to target RNA. At least, the comparative analysis of the various ligands that bind to this riboswitch shows that exploring a vast chemical space outside of the natural variations seen between cognate ligands is not a vain endeavor.</p><p hwp:id="p-33">The SAR approach in this study revealed several key aspects of designing therapeutics that target RNA. Starting with BRX857, we showed that a natural phosphate group required for binding could be substituted by a carboxylic group. Subsequent characterization of BRX1555 indicated that a negative charge could be bypassed altogether. Ribocil further demonstrated that an unrelated chemical scaffold supports a similar structural organization of the binding site. In spite of not interacting with A99, WG-3, a more recent discovery at Merck, stabilizes a similar architecture at the binding site, except for A48 at J3/4, which retains a conformation from the unbound state.<sup><xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-2" hwp:rel-id="ref-50">50</xref></sup> Notably, whereas 6–10 hydrogen bonds were observed between the various natural ligands and the RNA, the BRX compound series presented here relies on only 3–4, ribocil makes only one hydrogen bond to the RNA, and no hydrogen bonding is observed for WG-3. Hence, going from natural to synthetic ligands is synonymous with an increase in hydrophobic ligand-RNA contacts. This trend is reminiscent of modified aptamers with increased affinity for protein targets that displayed predominantly hydrophobic contacts at the aptamer-protein interface.<sup><xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-1" hwp:rel-id="ref-51">51</xref></sup> From these observations, we conclude that for specific and productive binding to this riboswitch, drugs need to comply with a set of principles that can be equally fulfilled by various interaction types, emphasizing the importance of hydrophobicity for selectivity (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Figure 6</xref>). What successful binders to this riboswitch have in common is that they simultaneously stabilize similar conformations for at least five of the six joining regions that interact with the ligand.</p><fig id="fig6" position="float" orientation="portrait" fig-type="figure" hwp:id="F7" hwp:rev-id="xref-fig-7-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Figure 6</label><caption hwp:id="caption-7"><title hwp:id="title-18">Generic principles for designing drugs that bind to the FMN riboswitch.</title><p hwp:id="p-34">The most critical aspects of ligand binding are shown in colors around a skeleton schematic of flavin-based chemical structures. Recognition patterns seen with all ligands except WG-3<sup><xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-3" hwp:rel-id="ref-50">50</xref></sup> are shown in gray. Dashed lines indicate putative functionalizations.</p></caption><graphic xlink:href="389148_fig6" position="float" orientation="portrait" hwp:id="graphic-7"/></fig><p hwp:id="p-35">Interestingly, a manual search for roseoflavin-like scaffolds within the library that led to the discovery of ribocil produced eight bioactive hits, seven of which contained aryl halides attached to an isoalloxazine heterocycle, some looking very close to 5FDQD.<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-6" hwp:rel-id="ref-32">32</xref></sup> In particular, the only difference between 5FDQD and the analog named ‘C003’ is the nature of the alkyl chain connecting the isoalloxazine heterocycle to the fluorobenzyl moiety (in C003, the chain contains only one carbon atom). Although C003 and related compounds were shown to have similar limitations to roseoflavin <italic toggle="yes">in vivo</italic>, supplying them to the structure-guided pipeline we describe here would have certainly accelerated the process of discovering 5FDQD. This striking example further attests of the promising future for 5FDQD and its derivatives in drug discovery, while stressing that although structure-based drug design and high throughput screening have both gained enough maturity to advance biomedicine, they could benefit from being further integrated with one another.</p></sec></sec><sec id="s3" hwp:id="sec-11"><title hwp:id="title-19">METHODS</title><sec id="s3a" hwp:id="sec-12"><title hwp:id="title-20">Chemical synthesis</title><p hwp:id="p-36">Compounds were either purchased (lumiflavin, 3B Scientific Corporation; roseoflavin, Toronto Research Chemicals; FMN, Sigma-Aldrich) or synthesized (RoFMN and all BRX compounds, see SI Methods). The progress of all reactions was monitored on Merck precoated silica gel plates (with fluorescence indicator UV254) using ethyl acetate/n-hexane as solvent system. Column chromatography was performed with Fluka silica gel 60 (230-400 mesh ASTM) with the solvent mixtures specified in the corresponding experiments. Spots were visualized by irradiation with ultraviolet light (254 nm). Melting points (mp) were taken in open capillaries on a Stuart melting point apparatus SMP11 and were uncorrected. Proton (<sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-3" hwp:rel-id="ref-1">1</xref></sup>H) and carbon (<sup><xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref></sup>C) NMR spectra were recorded on a Bruker Avance 500 (500.13 MHz for <sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-4" hwp:rel-id="ref-1">1</xref></sup>H; 125.76 MHz for <sup><xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-3" hwp:rel-id="ref-13">13</xref></sup>C) using DMSO-d<sub>6</sub> as solvent. Chemical shifts are given in parts per million (ppm) (δ relative to residual solvent peak for <sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-5" hwp:rel-id="ref-1">1</xref></sup>H and <sup><xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-4" hwp:rel-id="ref-13">13</xref></sup>C). Elemental analysis was performed on a Perkin-Elmer PE 2400 CHN elemental analyzer and a vario MICRO cube elemental analyzer (Elementar Analysensysteme GmbH). IR spectra were recorded on a Varian 800 FT-IR Scimitar series. Optical rotation was given in deg cm<sup><xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">3</xref></sup> g<sup>-1</sup> dm<sup>-1</sup>. High-resolution mass spectrometry (HRMS) analysis was performed using a UHR-TOF maXis 4G instrument (Bruker Daltonics). If necessary, purity was determined by high performance liquid chromatography (HPLC) using an Elite LaChrom system [Hitachi L-2130 (pump) and L-2400 (UV-detector)] and a Phenomenex Luna C18 column. Purity of all final compounds was 95% or higher.</p></sec><sec id="s3b" hwp:id="sec-13"><title hwp:id="title-21">In-line probing assays</title><p hwp:id="p-37">The 165 <italic toggle="yes">ribD</italic> RNA used for in-line probing assays was prepared by <italic toggle="yes">in vitro</italic> transcription using a template generated from genomic DNA from <italic toggle="yes">Bacillus subtilis</italic> strain 168 (American Type Culture Collection, Manassas, VA). RNA transcripts were dephosphorylated, 5′ <sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-7" hwp:rel-id="ref-32">32</xref></sup>P-labeled, and subsequently subjected to in-line probing using protocols similar to those described previously.<sup><xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-2" hwp:rel-id="ref-39">39</xref></sup> The <italic toggle="yes">K<sub>D</sub></italic> for each ligand was derived by quantifying the amount of RNA cleaved in regions where a change was observed (regions 1–6 on Figure S1), over a range of ligand concentrations. The fraction cleaved, x, was calculated by assuming the maximal extent of cleavage is observed in the absence of ligand and the minimal extent of cleavage is observed in the presence of the highest ligand concentration. The apparent <italic toggle="yes">K<sub>D</sub></italic> was determined by using GraphPad Prism 6 or Kaleidagraph software to fit the plot of the fraction cleaved, <italic toggle="yes">fc</italic>, versus the ligand concentration, [L], to the following equation: <italic toggle="yes">fc</italic> = <italic toggle="yes">K<sub>D</sub></italic> ([L] + <italic toggle="yes">K<sub>D</sub></italic>)<sup>-1</sup>.</p></sec><sec id="s3c" hwp:id="sec-14"><title hwp:id="title-22"><italic toggle="yes">In vitro</italic> RNA transcription termination assays</title><p hwp:id="p-38">Single-round RNA transcription termination assays were conducted following protocols adapted from a previously described method.<sup><xref ref-type="bibr" rid="c54" hwp:id="xref-ref-54-1" hwp:rel-id="ref-54">54</xref></sup> The DNA template covered the region −382 to +13 (relative to the start of translation) of the <italic toggle="yes">B. subtilis ribD</italic> gene and was generated by PCR from genomic DNA from the 168 strain of <italic toggle="yes">B. subtilis</italic>. To initiate transcription and form stalled complexes, each sample was incubated at 37°C for 10 min and contained 1 pmole DNA template, 0.17 mM ApA dinucleotide (TriLink Biotechnologies, San Diego, CA), 2.5 μM each of ATP, GTP, and UTP, plus 2 μCi 5’-[α-<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-8" hwp:rel-id="ref-32">32</xref></sup>P]-UTP, and 0.4 U <italic toggle="yes">E. coli</italic> RNA polymerase holoenzyme (Epicenter, Madison, WI) in 10 μl of 80 mM Tris-HCl (pH 8.0 at 23 °C), 20 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.1 mM EDTA and 0.01 mg/mL bovine serum albumin (BSA, New England Biolabs). Halted complexes were restarted by the simultaneous addition of a mixture of all four NTPs (at a final concentration of 50 μM) and 0.2 mg/mL heparin to prevent re-initiation, as well as varying concentrations of ligand as indicated to yield a final volume of 12.5 μl in a buffer containing 150 mM Tris-HCl (pH 8.0 at 23 °C), 20 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.1 mM EDTA and 0.01 mg/mL BSA. Reactions were incubated for an additional 20 min at 37 °C, and the products were separated by denaturing 10% polyacrylamide gel electrophoresis (PAGE) followed by quantitation of the fraction terminated at each ligand concentration by using a phosphorimager (Storm 860, GE Healthcare Life Sciences).</p></sec><sec id="s3d" hwp:id="sec-15"><title hwp:id="title-23">SHAPE probing</title><p hwp:id="p-39">Experiments were performed according to published SHAPE protocols.<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-3" hwp:rel-id="ref-24">24</xref>, <xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-14" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-2" hwp:rel-id="ref-40">40</xref></sup> The <italic toggle="yes">B. subtilis</italic> RNA containing residues 23–166 of the <italic toggle="yes">165 ribD</italic> element<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-15" hwp:rel-id="ref-30">30</xref></sup> was diluted to a concentration of 2.0 μM in 50 mM HEPES pH 8.0, and incubated for 2 min at 95 °C followed by 3 min at 4 °C. Two parts of this RNA solution were combined to one part of a folding buffer so that the following buffer and ionic concentrations would be reached: 100 mM KCl, 0–15 mM MgCl2 (chosen [MgCl2]: 0, 0.1, 0.5, 2.0, 15.0 mM, 50 mM HEPES pH 8.0, ±10 or 100 μM ligand. This mixture was incubated for 10 min at 37 °C. Two experiments were carried out for each tested compound at each ligand concentration. NMIA modification was performed in the presence of 6.5 mM NMIA for 45 min at 37 °C, at each magnesium concentration specified above. Samples were precipitated for 16 h at −20 °C in 70% EtOH, 100 mM Na-acetate pH 5.3, in the presence of 20 μg of glycogen, centrifuged for 35 min at 13500xg, dried for 10 min under vacuum and resuspended in 9.0 μL 0.5x T.E. buffer (10 mM Tris, 1mM EDTA, pH 8.0). Primer extension by reverse transcription was performed as described,<sup><xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-3" hwp:rel-id="ref-40">40</xref></sup> except that the extension step was performed for 15 min at 50 °C. Primers used for the extension were designed to pair with a binding site in the 3’ structure cassette. Extensions products were resolved by analytical gel electrophoresis, as described.<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-4" hwp:rel-id="ref-24">24</xref></sup> The gel image (.gel file; Figure S2) was aligned in SAFA v.1.1.<sup><xref ref-type="bibr" rid="c55" hwp:id="xref-ref-55-2" hwp:rel-id="ref-55">55</xref>–<xref ref-type="bibr" rid="c56" hwp:id="xref-ref-56-2" hwp:rel-id="ref-56">56</xref></sup></p></sec><sec id="s3e" hwp:id="sec-16"><title hwp:id="title-24">Crystallization</title><p hwp:id="p-40">Crystals of complexes with BRX1151, BRX1354 and BRX 1555 were obtained using the hanging-drop vapor diffusion method, following previously published procedures (see SI Methods).<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-16" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-11" hwp:rel-id="ref-33">33</xref></sup> The BRX1354 and BRX1555 complexes were crystallized using RNA sequences and minor variations of the crystallization conditions from the first published structure of the FMN riboswitch<sup><xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-12" hwp:rel-id="ref-33">33</xref></sup> (200 mM MgCl<sub>2</sub>, 100 mM MES-NaOH (pH 6.5), 8.5% w/v polyethylene glycol 4000 (BRX1354); 200 mM MgCl2, 100 mM MES-NaOH (pH 6.5), 8.5% w/v polyethylene glycol 4000, 2.5% DMSO (BRX1555); 20°C), while the BRX1151 complex was crystallized using alternative sequences and crystallization conditions<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-17" hwp:rel-id="ref-30">30</xref></sup> (320 mM MgCl<sub>2</sub>, 10 mM Tris-HCl (pH 8.4), 8.25% w/v polyethylene glycol 4000; 20 °C). Cryoprotectant was introduced gradually to final concentrations of 10–13.5 % PEG 4000, 10% sucrose and 15% glycerol (BRX1354, BRX1555), or directly to 25% glycerol (BRX1151). Crystals were then harvested with nylon loops and flash cooled by plunging into liquid nitrogen.</p></sec><sec id="s3f" hwp:id="sec-17"><title hwp:id="title-25">Data collection and processing</title><p hwp:id="p-41">Diffraction data for BRX1151 were collected on the X25 beamline at the National Synchrotron Light Source (NSLS) at Brookhaven National Laboratory, as part of the mail-in crystallography program,<sup><xref ref-type="bibr" rid="c57" hwp:id="xref-ref-57-1" hwp:rel-id="ref-57">57</xref></sup> and processed via autoPROC<sup><xref ref-type="bibr" rid="c58" hwp:id="xref-ref-58-1" hwp:rel-id="ref-58">58</xref></sup> (space group P3<sub>1</sub>21). Diffraction data for BRX1354 and BRX1555 were collected on the X29A beamline at NSLS. Merged data from two (BRX1555) or three (BRX1354) crystals were corrected for anisotropy and rescaled with the Diffraction Anisotropy Server, [<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.doe-mbi.ucla.edu/~sawaya/anisoscale" ext-link-type="uri" xlink:href="http://www.doe-mbi.ucla.edu/~sawaya/anisoscale" hwp:id="ext-link-1">http://www.doe-mbi.ucla.edu/~sawaya/anisoscale</ext-link>], indexed in the trigonal space group P3<sub>1</sub>21, and scaled using DENZO and SCALEPACK in the program suite HKL2000.<sup><xref ref-type="bibr" rid="c59" hwp:id="xref-ref-59-1" hwp:rel-id="ref-59">59</xref></sup></p></sec><sec id="s3g" hwp:id="sec-18"><title hwp:id="title-26">Structure determination</title><p hwp:id="p-42">For all crystal structures presented, atomic coordinates from the split RNA FMN riboswitch crystal structure PDB code 3F4E were used as a starting model for a molecular replacement search using PHASER.<sup><xref ref-type="bibr" rid="c60" hwp:id="xref-ref-60-1" hwp:rel-id="ref-60">60</xref></sup> Ligand, ions and solvent molecules were intentionally omitted from the search model. A solution was successfully obtained in space group P3<sub>1</sub>21 for one riboswitch in an asymmetric unit with high scores (RFZ, TFZ &gt; 10) for the rotation function, translation function, least-likelihood gain and with no atom clashes. A SMILES string for each ligand was generated and supplied to GRADE (Global Phasing, UK) to obtain an atomic model and restraints for refinement in BUSTER-TNT.<sup><xref ref-type="bibr" rid="c61" hwp:id="xref-ref-61-1" hwp:rel-id="ref-61">61</xref></sup> After iterative rounds of manual model adjustment and refinement, the ligands were placed in sigma-A weighted F<sub>o</sub>-F<sub>c</sub> maps. Given the medium resolution of the structures, solvent density was left unassigned, except for density peaks in which we tentatively placed water molecules, anionic, and cationic ions, in agreement with previous rules.<sup><xref ref-type="bibr" rid="c62" hwp:id="xref-ref-62-1" hwp:rel-id="ref-62">62</xref>–<xref ref-type="bibr" rid="c65" hwp:id="xref-ref-65-1" hwp:rel-id="ref-65">65</xref></sup></p></sec></sec><sec hwp:id="sec-19"><title hwp:id="title-27">CONTRIBUTIONS</title><p hwp:id="p-43">Q.V., K.F.B., P.C. and R.T.B. designed the study. P.A., P.C., J.B., P.W. led the compound design and chemical optimization efforts. J.B., H.K., K.W.K, P.W., and J.W. synthesized and purified RoFMN, BRX247, BRX830, BRX857, BRX897, BRX931, BRX1027, BRX1224 and BRX1354. R.C.G. and H.J.S. synthesized and purified BRX1151 and BRX1555. K.F.B. carried out the functional and in-line probing assays. R.K.S. crystallized the BRX1354 and BRX1555 complexes and solved their structures. Q.V. and E.M. performed the SHAPE mapping experiments, crystallized the BRX1151 complex and solved its structure. Q.V. and F.R. finalized the refinement of all structures. Q.V., K.F.B. and R.T.B. wrote the manuscript. All authors have given approval to the final version of the manuscript.</p></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-28">ACKNOWLEDGEMENTS</title><p hwp:id="p-44">We wish to thank Annie Héroux at Brookhaven National Laboratory for data collection and processing of the BRX1151 complex; Raymond S. Brown, Eric Fontano, and Andre White for contributions to the crystallization and structure determinations of the BRX1354 and BRX1555 complexes; Filip Leonarski and Pascal Auffinger for helpful discussions about solvent; Ron Breaker for support. R.T.B. acknowledges support by a grant from the National Institutes of Health (R01 GM073850). This research used beamline X25 of the National Synchrotron Light Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Brookhaven National Laboratory under Contract No. DE-AC02-98CH10886.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-29">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1 xref-ref-1-2 xref-ref-1-3 xref-ref-1-4 xref-ref-1-5"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Gallego J."><surname>Gallego</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Varani G."><surname>Varani</surname>, <given-names>G.</given-names></string-name>, <article-title hwp:id="article-title-2">Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges</article-title>. <source hwp:id="source-1">Acc Chem Res</source> <year>2001</year>, <volume>34</volume> (<issue>10</issue>), <fpage>836</fpage>–<lpage>43</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Moazed D."><surname>Moazed</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Noller H. F."><surname>Noller</surname>, <given-names>H. F.</given-names></string-name>, <article-title hwp:id="article-title-3">Interaction of antibiotics with functional sites in 16S ribosomal RNA</article-title>. <source hwp:id="source-2">Nature</source> <year>1987</year>, <volume>327</volume> (<issue>6121</issue>), <fpage>389</fpage>–<lpage>94</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Ippolito J. A."><surname>Ippolito</surname>, <given-names>J. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kanyo Z. F."><surname>Kanyo</surname>, <given-names>Z. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang D."><surname>Wang</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Franceschi F. J."><surname>Franceschi</surname>, <given-names>F. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Moore P. B."><surname>Moore</surname>, <given-names>P. B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Steitz T. A."><surname>Steitz</surname>, <given-names>T. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Duffy E. M."><surname>Duffy</surname>, <given-names>E. M.</given-names></string-name>, <article-title hwp:id="article-title-4">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</article-title>. <source hwp:id="source-3">J Med Chem</source> <year>2008</year>, <volume>51</volume> (<issue>12</issue>), <fpage>3353</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Wilson D. N."><surname>Wilson</surname>, <given-names>D. N.</given-names></string-name>, <article-title hwp:id="article-title-5">Ribosome-targeting antibiotics and mechanisms of bacterial resistance</article-title>. <source hwp:id="source-4">Nat Rev Microbiol</source> <year>2014</year>, <volume>12</volume> (<issue>1</issue>), <fpage>35</fpage>–<lpage>48</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Chakradhar S."><surname>Chakradhar</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bringing RNA"><surname>Bringing</surname> <given-names>RNA</given-names></string-name> <article-title hwp:id="article-title-6">into the fold: Small molecules find new targets in RNA to combat disease</article-title>. <source hwp:id="source-5">Nat Med</source> <year>2017</year>, <volume>23</volume> (<issue>5</issue>), <fpage>532</fpage>–<lpage>534</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Mullard A."><surname>Mullard</surname>, <given-names>A.</given-names></string-name>, <article-title hwp:id="article-title-7">Small molecules against RNA targets attract big backers</article-title>. <source hwp:id="source-6">Nat Rev Drug Discov</source> <year>2017</year>, <volume>16</volume> (<issue>12</issue>), <fpage>813</fpage>–<lpage>815</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Blount K. F."><surname>Blount</surname>, <given-names>K. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-8">Riboswitches as antibacterial drug targets</article-title>. <source hwp:id="source-7">Nature Biotechnology</source> <year>2006</year>, <volume>24</volume> (<issue>12</issue>), <fpage>1558</fpage>–<lpage>1564</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Mandal M."><surname>Mandal</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Boese B."><surname>Boese</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Barrick J. E."><surname>Barrick</surname>, <given-names>J. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Winkler W. C."><surname>Winkler</surname>, <given-names>W. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-9">Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria</article-title>. <source hwp:id="source-8">Cell</source> <year>2003</year>, <volume>113</volume> (<issue>5</issue>), <fpage>577</fpage>–<lpage>86</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="other" citation-type="journal" ref:id="389148v1.9" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Roth A."><surname>Roth</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R."><surname>Breaker</surname>, <given-names>R.</given-names></string-name>, <article-title hwp:id="article-title-10">The Structural and Functional Diversity of Metabolite-Binding Riboswitches</article-title>. <source hwp:id="source-9">Annual review of biochemistry</source> <year>2009</year>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Vicens Q."><surname>Vicens</surname>, <given-names>Q.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Westhof E."><surname>Westhof</surname>, <given-names>E.</given-names></string-name>, <article-title hwp:id="article-title-11">RNA as a drug target: the case of aminoglycosides</article-title>. <source hwp:id="source-10">ChemBioChem</source> <year>2003</year>, <volume>4</volume> (<issue>10</issue>), <fpage>1018</fpage>–<lpage>1023</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Montange R. K."><surname>Montange</surname>, <given-names>R. K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mondragon E."><surname>Mondragon</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="van Tyne D."><surname>van Tyne</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Garst A. D."><surname>Garst</surname>, <given-names>A. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ceres P."><surname>Ceres</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-12">Discrimination between closely related cellular metabolites by the SAM-I riboswitch</article-title>. <source hwp:id="source-11">J Mol Biol</source> <year>2010</year>, <volume>396</volume> (<issue>3</issue>), <fpage>761</fpage>–<lpage>72</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Trausch J. J."><surname>Trausch</surname>, <given-names>J. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-13">A disconnect between high-affinity binding and efficient regulation by antifolates and purines in the tetrahydrofolate riboswitch</article-title>. <source hwp:id="source-12">Chem Biol</source> <year>2014</year>, <volume>21</volume> (<issue>2</issue>), <fpage>205</fpage>–<lpage>16</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2 xref-ref-13-3 xref-ref-13-4"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Edwards T. E."><surname>Edwards</surname>, <given-names>T. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ferre-D’Amare A. R."><surname>Ferre-D’Amare</surname>, <given-names>A. R.</given-names></string-name>, <article-title hwp:id="article-title-14">Crystal structures of the thi-box riboswitch bound to thiamine pyrophosphate analogs reveal adaptive RNA-small molecule recognition</article-title>. <source hwp:id="source-13">Structure</source> <year>2006</year>, <volume>14</volume> (<issue>9</issue>), <fpage>1459</fpage>–<lpage>68</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Blount K. F."><surname>Blount</surname>, <given-names>K. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang J. X."><surname>Wang</surname>, <given-names>J. X.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Lim J."><surname>Lim</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sudarsan N."><surname>Sudarsan</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-15">Antibacterial lysine analogs that target lysine riboswitches</article-title>. <source hwp:id="source-14">Nature Chemical Biology</source> <year>2007</year>, <volume>3</volume> (<issue>1</issue>), <fpage>44</fpage>–<lpage>49</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Ataide S. F."><surname>Ataide</surname>, <given-names>S. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wilson S. N."><surname>Wilson</surname>, <given-names>S. N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Dang S."><surname>Dang</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Rogers T. E."><surname>Rogers</surname>, <given-names>T. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Roy B."><surname>Roy</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Banerjee R."><surname>Banerjee</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Henkin T. M."><surname>Henkin</surname>, <given-names>T. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ibba M."><surname>Ibba</surname>, <given-names>M.</given-names></string-name>, <article-title hwp:id="article-title-16">Mechanisms of resistance to an amino acid antibiotic that targets translation</article-title>. <source hwp:id="source-15">ACS Chem Biol</source> <year>2007</year>, <volume>2</volume> (<issue>12</issue>), <fpage>819</fpage>–<lpage>27</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Otani S."><surname>Otani</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Takatsu M."><surname>Takatsu</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nakano M."><surname>Nakano</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kasai S."><surname>Kasai</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Miura R."><surname>Miura</surname>, <given-names>R.</given-names></string-name>, <article-title hwp:id="article-title-17">Letter: Roseoflavin, a new antimicrobial pigment from Streptomyces</article-title>. <source hwp:id="source-16">J Antibiot (Tokyo)</source> <year>1974</year>, <volume>27</volume> (<issue>1</issue>), <fpage>86</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1 xref-ref-17-2 xref-ref-17-3 xref-ref-17-4 xref-ref-17-5 xref-ref-17-6 xref-ref-17-7 xref-ref-17-8"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.17" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Lee E."><surname>Lee</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Blount K."><surname>Blount</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R."><surname>Breaker</surname>, <given-names>R.</given-names></string-name>, <article-title hwp:id="article-title-18">Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression</article-title>. <source hwp:id="source-17">RNA biology</source> <year>2009</year>, <volume>6</volume> (<issue>2</issue>).</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Matzner D."><surname>Matzner</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mayer G."><surname>Mayer</surname>, <given-names>G.</given-names></string-name>, <article-title hwp:id="article-title-19">(Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds</article-title>. <source hwp:id="source-18">J Med Chem</source> <year>2015</year>, <volume>58</volume> (<issue>8</issue>), <fpage>3275</fpage>–<lpage>86</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Kim J. N."><surname>Kim</surname>, <given-names>J. N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Blount K. F."><surname>Blount</surname>, <given-names>K. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Puskarz I."><surname>Puskarz</surname>, <given-names>I.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Lim J."><surname>Lim</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Link K. H."><surname>Link</surname>, <given-names>K. H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-20">Design and antimicrobial action of purine analogues that bind Guanine riboswitches</article-title>. <source hwp:id="source-19">ACS Chemical Biology</source> <year>2009</year>, <volume>4</volume> (<issue>11</issue>), <fpage>915</fpage>–<lpage>927</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Mulhbacher J."><surname>Mulhbacher</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Brouillette E."><surname>Brouillette</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Allard M."><surname>Allard</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fortier L. C."><surname>Fortier</surname>, <given-names>L. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Malouin F."><surname>Malouin</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Lafontaine D. A."><surname>Lafontaine</surname>, <given-names>D. A.</given-names></string-name>, <article-title hwp:id="article-title-21">Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways</article-title>. <source hwp:id="source-20">PLoS Pathog</source> <year>2010</year>, <volume>6</volume> (<issue>4</issue>), <fpage>e1000865</fpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Chen L."><surname>Chen</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Cressina E."><surname>Cressina</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Leeper F. J."><surname>Leeper</surname>, <given-names>F. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Smith A. G."><surname>Smith</surname>, <given-names>A. G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Abell C."><surname>Abell</surname>, <given-names>C.</given-names></string-name>, <article-title hwp:id="article-title-22">A fragment-based approach to identifying ligands for riboswitches</article-title>. <source hwp:id="source-21">ACS Chem Biol</source> <year>2010</year>, <volume>5</volume> (<issue>4</issue>), <fpage>355</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Gilbert S. D."><surname>Gilbert</surname>, <given-names>S. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mediatore S. J."><surname>Mediatore</surname>, <given-names>S. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-23">Modified pyrimidines specifically bind the purine riboswitch</article-title>. <source hwp:id="source-22">J Am Chem Soc</source> <year>2006</year>, <volume>128</volume> (<issue>44</issue>), <fpage>14214</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2 xref-ref-23-3 xref-ref-23-4 xref-ref-23-5"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Winkler W. C."><surname>Winkler</surname>, <given-names>W. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Cohen-Chalamish S."><surname>Cohen-Chalamish</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-24">An mRNA structure that controls gene expression by binding FMN</article-title>. <source hwp:id="source-23">Proc Natl Acad Sci U S A</source> <year>2002</year>, <volume>99</volume> (<issue>25</issue>), <fpage>15908</fpage>–<lpage>13</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1 xref-ref-24-2 xref-ref-24-3 xref-ref-24-4"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Stoddard C. D."><surname>Stoddard</surname>, <given-names>C. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Gilbert S. D."><surname>Gilbert</surname>, <given-names>S. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-25">Ligand-dependent folding of the three-way junction in the purine riboswitch</article-title>. <source hwp:id="source-24">RNA</source> <year>2008</year>, <volume>14</volume> (<issue>4</issue>), <fpage>675</fpage>–<lpage>84</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1 xref-ref-25-2"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Baird N. J."><surname>Baird</surname>, <given-names>N. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ferre-D’Amare A. R."><surname>Ferre-D’Amare</surname>, <given-names>A. R.</given-names></string-name>, <article-title hwp:id="article-title-26">Idiosyncratically tuned switching behavior of riboswitch aptamer domains revealed by comparative small-angle X-ray scattering analysis</article-title>. <source hwp:id="source-25">RNA</source> <year>2010</year>, <volume>16</volume> (<issue>3</issue>), <fpage>598</fpage>–<lpage>609</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Gilbert S. D."><surname>Gilbert</surname>, <given-names>S. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Stoddard C. D."><surname>Stoddard</surname>, <given-names>C. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wise S. J."><surname>Wise</surname>, <given-names>S. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-27">Thermodynamic and kinetic characterization of ligand binding to the purine riboswitch aptamer domain</article-title>. <source hwp:id="source-26">J Mol Biol</source> <year>2006</year>, <volume>359</volume> (<issue>3</issue>), <fpage>754</fpage>–<lpage>68</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Buck J."><surname>Buck</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Furtig B."><surname>Furtig</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Noeske J."><surname>Noeske</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wohnert J."><surname>Wohnert</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schwalbe H."><surname>Schwalbe</surname>, <given-names>H.</given-names></string-name>, <article-title hwp:id="article-title-28">Time-resolved NMR methods resolving ligand-induced RNA folding at atomic resolution</article-title>. <source hwp:id="source-27">P Natl Acad Sci USA</source> <year>2007</year>, <volume>104</volume> (<issue>40</issue>), <fpage>15699</fpage>–<lpage>15704</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Stagno J. R."><surname>Stagno</surname>, <given-names>J. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Liu Y."><surname>Liu</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bhandari Y. R."><surname>Bhandari</surname>, <given-names>Y. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Conrad C. E."><surname>Conrad</surname>, <given-names>C. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Panja S."><surname>Panja</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Swain M."><surname>Swain</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fan L."><surname>Fan</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nelson G."><surname>Nelson</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Li C."><surname>Li</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wendel D. R."><surname>Wendel</surname>, <given-names>D. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="White T. A."><surname>White</surname>, <given-names>T. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Coe J. D."><surname>Coe</surname>, <given-names>J. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wiedorn M. O."><surname>Wiedorn</surname>, <given-names>M. O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Knoska J."><surname>Knoska</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Oberthuer D."><surname>Oberthuer</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Tuckey R. A."><surname>Tuckey</surname>, <given-names>R. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Yu P."><surname>Yu</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Dyba M."><surname>Dyba</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Tarasov S. G."><surname>Tarasov</surname>, <given-names>S. G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Weierstall U."><surname>Weierstall</surname>, <given-names>U.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Grant T. D."><surname>Grant</surname>, <given-names>T. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schwieters C. D."><surname>Schwieters</surname>, <given-names>C. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zhang J."><surname>Zhang</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ferre-D’Amare A. R."><surname>Ferre-D’Amare</surname>, <given-names>A. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fromme P."><surname>Fromme</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Draper D. E."><surname>Draper</surname>, <given-names>D. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Liang M."><surname>Liang</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Hunter M. S."><surname>Hunter</surname>, <given-names>M. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Boutet S."><surname>Boutet</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Tan K."><surname>Tan</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zuo X."><surname>Zuo</surname>, <given-names>X.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ji X."><surname>Ji</surname>, <given-names>X.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Barty A."><surname>Barty</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zatsepin N. A."><surname>Zatsepin</surname>, <given-names>N. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Chapman H. N."><surname>Chapman</surname>, <given-names>H. N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Spence J. C."><surname>Spence</surname>, <given-names>J. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Woodson S. A."><surname>Woodson</surname>, <given-names>S. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang Y. X."><surname>Wang</surname>, <given-names>Y. X.</given-names></string-name>, <article-title hwp:id="article-title-29">Structures of riboswitch RNA reaction states by mix-and-inject XFEL serial crystallography</article-title>. <source hwp:id="source-28">Nature</source> <year>2017</year>, <volume>541</volume> (<issue>7636</issue>), <fpage>242</fpage>–<lpage>246</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Stoddard C. D."><surname>Stoddard</surname>, <given-names>C. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Montange R. K."><surname>Montange</surname>, <given-names>R. K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Hennelly S. P."><surname>Hennelly</surname>, <given-names>S. P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Rambo R. P."><surname>Rambo</surname>, <given-names>R. P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sanbonmatsu K. Y."><surname>Sanbonmatsu</surname>, <given-names>K. Y.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-30">Free state conformational sampling of the SAM-I riboswitch aptamer domain</article-title>. <source hwp:id="source-29">Structure</source> <year>2010</year>, <volume>18</volume> (<issue>7</issue>), <fpage>787</fpage>–<lpage>97</lpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1 xref-ref-30-2 xref-ref-30-3 xref-ref-30-4 xref-ref-30-5 xref-ref-30-6 xref-ref-30-7 xref-ref-30-8 xref-ref-30-9 xref-ref-30-10 xref-ref-30-11 xref-ref-30-12 xref-ref-30-13 xref-ref-30-14 xref-ref-30-15 xref-ref-30-16 xref-ref-30-17"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Vicens Q."><surname>Vicens</surname>, <given-names>Q.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mondragon E."><surname>Mondragon</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Batey R. T."><surname>Batey</surname>, <given-names>R. T.</given-names></string-name>, <article-title hwp:id="article-title-31">Molecular sensing by the aptamer domain of the FMN riboswitch: a general model for ligand binding by conformational selection</article-title>. <source hwp:id="source-30">Nucleic Acids Res</source> <year>2011</year>, <volume>39</volume> (<issue>19</issue>), <fpage>8586</fpage>–<lpage>98</lpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1 xref-ref-31-2 xref-ref-31-3 xref-ref-31-4 xref-ref-31-5 xref-ref-31-6"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Blount K. F."><surname>Blount</surname>, <given-names>K. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Megyola C."><surname>Megyola</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Plummer M."><surname>Plummer</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Osterman D."><surname>Osterman</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="O&amp;Connell T."><surname>O&amp;Connell</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Aristoff P."><surname>Aristoff</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Quinn C."><surname>Quinn</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Chrusciel R. A."><surname>Chrusciel</surname>, <given-names>R. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Poel T. J."><surname>Poel</surname>, <given-names>T. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schostarez H. J."><surname>Schostarez</surname>, <given-names>H. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Stewart C. A."><surname>Stewart</surname>, <given-names>C. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Walker D. P."><surname>Walker</surname>, <given-names>D. P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wuts P. G. M."><surname>Wuts</surname>, <given-names>P. G. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-32">Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora</article-title>. <source hwp:id="source-31">Antimicrobial agents and chemotherapy</source> <year>2015</year>, <volume>59</volume> (<issue>9</issue>), <fpage>5736</fpage>–<lpage>5746</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1 xref-ref-32-2 xref-ref-32-3 xref-ref-32-4 xref-ref-32-5 xref-ref-32-6 xref-ref-32-7 xref-ref-32-8"><label>32.</label><citation publication-type="other" citation-type="journal" ref:id="389148v1.32" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Howe J. A."><surname>Howe</surname>, <given-names>J. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang H."><surname>Wang</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fischmann T. O."><surname>Fischmann</surname>, <given-names>T. O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Balibar C. J."><surname>Balibar</surname>, <given-names>C. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Xiao L."><surname>Xiao</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Galgoci A. M."><surname>Galgoci</surname>, <given-names>A. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Malinverni J. C."><surname>Malinverni</surname>, <given-names>J. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mayhood T."><surname>Mayhood</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Villafania A."><surname>Villafania</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nahvi A."><surname>Nahvi</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Murgolo N."><surname>Murgolo</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Barbieri C. M."><surname>Barbieri</surname>, <given-names>C. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mann P. A."><surname>Mann</surname>, <given-names>P. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Carr D."><surname>Carr</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Xia E."><surname>Xia</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zuck P."><surname>Zuck</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Riley D."><surname>Riley</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Painter R. E."><surname>Painter</surname>, <given-names>R. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Walker S. S."><surname>Walker</surname>, <given-names>S. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sherborne B."><surname>Sherborne</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="de Jesus R."><surname>de Jesus</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Pan W."><surname>Pan</surname>, <given-names>W.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Plotkin M. A."><surname>Plotkin</surname>, <given-names>M. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wu J."><surname>Wu</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Rindgen D."><surname>Rindgen</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Cummings J."><surname>Cummings</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Garlisi C. G."><surname>Garlisi</surname>, <given-names>C. G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zhang R."><surname>Zhang</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sheth P. R."><surname>Sheth</surname>, <given-names>P. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Gill C. J."><surname>Gill</surname>, <given-names>C. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Tang H."><surname>Tang</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Roemer T."><surname>Roemer</surname>, <given-names>T.</given-names></string-name>, <article-title hwp:id="article-title-33">Selective small-molecule inhibition of an RNA structural element</article-title>. <source hwp:id="source-32">Nature</source> <year>2015</year>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1 xref-ref-33-2 xref-ref-33-3 xref-ref-33-4 xref-ref-33-5 xref-ref-33-6 xref-ref-33-7 xref-ref-33-8 xref-ref-33-9 xref-ref-33-10 xref-ref-33-11 xref-ref-33-12"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Serganov A."><surname>Serganov</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Huang L."><surname>Huang</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Patel D. J."><surname>Patel</surname>, <given-names>D. J.</given-names></string-name>, <article-title hwp:id="article-title-34">Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch</article-title>. <source hwp:id="source-33">Nature</source> <year>2009</year>, <volume>458</volume> (<issue>7235</issue>), <fpage>233</fpage>–<lpage>237</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Garcia Angulo V. A."><surname>Garcia Angulo</surname>, <given-names>V. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bonomi H. R."><surname>Bonomi</surname>, <given-names>H. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Posadas D. M."><surname>Posadas</surname>, <given-names>D. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Serer M. I."><surname>Serer</surname>, <given-names>M. I.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Torres A. G."><surname>Torres</surname>, <given-names>A. G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zorreguieta A."><surname>Zorreguieta</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Goldbaum F. A."><surname>Goldbaum</surname>, <given-names>F. A.</given-names></string-name>, <article-title hwp:id="article-title-35">Identification and characterization of RibN, a novel family of riboflavin transporters from Rhizobium leguminosarum and other proteobacteria</article-title>. <source hwp:id="source-34">J Bacteriol</source> <year>2013</year>, <volume>195</volume> (<issue>20</issue>), <fpage>4611</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Gutierrez-Preciado A."><surname>Gutierrez-Preciado</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Torres A. G."><surname>Torres</surname>, <given-names>A. G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Merino E."><surname>Merino</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bonomi H. R."><surname>Bonomi</surname>, <given-names>H. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Goldbaum F. A."><surname>Goldbaum</surname>, <given-names>F. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Garcia-Angulo V. A."><surname>Garcia-Angulo</surname>, <given-names>V. A.</given-names></string-name>, <article-title hwp:id="article-title-36">Extensive Identification of Bacterial Riboflavin Transporters and Their Distribution across Bacterial Species</article-title>. <source hwp:id="source-35">PLoS One</source> <year>2015</year>, <volume>10</volume> (<issue>5</issue>), <fpage>e0126124</fpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Cecchini G."><surname>Cecchini</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Perl M."><surname>Perl</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Lipsick J."><surname>Lipsick</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Singer T. P."><surname>Singer</surname>, <given-names>T. P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kearney E. B."><surname>Kearney</surname>, <given-names>E. B.</given-names></string-name>, <article-title hwp:id="article-title-37">Transport and binding of riboflavin by Bacillus subtilis</article-title>. <source hwp:id="source-36">J Biol Chem</source> <year>1979</year>, <volume>254</volume> (<issue>15</issue>), <fpage>7295</fpage>–<lpage>301</lpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Vogl C."><surname>Vogl</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Grill S."><surname>Grill</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schilling O."><surname>Schilling</surname>, <given-names>O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Stulke J."><surname>Stulke</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mack M."><surname>Mack</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Stolz J."><surname>Stolz</surname>, <given-names>J.</given-names></string-name>, <article-title hwp:id="article-title-38">Characterization of riboflavin (vitamin B2) transport proteins from Bacillus subtilis and Corynebacterium glutamicum</article-title>. <source hwp:id="source-37">J Bacteriol</source> <year>2007</year>, <volume>189</volume> (<issue>20</issue>), <fpage>7367</fpage>–<lpage>75</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Pedrolli D. B."><surname>Pedrolli</surname>, <given-names>D. B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Jankowitsch F."><surname>Jankowitsch</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schwarz J."><surname>Schwarz</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Langer S."><surname>Langer</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nakanishi S."><surname>Nakanishi</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Frei E."><surname>Frei</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mack M."><surname>Mack</surname>, <given-names>M.</given-names></string-name>, <article-title hwp:id="article-title-39">Riboflavin analogs as antiinfectives: occurrence, mode of action, metabolism and resistance</article-title>. <source hwp:id="source-38">Curr Pharm Des</source> <year>2013</year>, <volume>19</volume> (<issue>14</issue>), <fpage>2552</fpage>–<lpage>60</lpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1 xref-ref-39-2"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Regulski E. E."><surname>Regulski</surname>, <given-names>E. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Breaker R. R."><surname>Breaker</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-40">In-line probing analysis of riboswitches</article-title>. <source hwp:id="source-39">Methods Mol Biol</source> <year>2008</year>, <volume>419</volume>, <fpage>53</fpage>–<lpage>67</lpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1 xref-ref-40-2 xref-ref-40-3"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Wilkinson K. A."><surname>Wilkinson</surname>, <given-names>K. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Merino E. J."><surname>Merino</surname>, <given-names>E. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Weeks K. M."><surname>Weeks</surname>, <given-names>K. M.</given-names></string-name>, <article-title hwp:id="article-title-41">Selective 2ʹ-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution</article-title>. <source hwp:id="source-40">Nat Protoc</source> <year>2006</year>, <volume>1</volume> (<issue>3</issue>), <fpage>1610</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Di L."><surname>Di</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kerns E. H."><surname>Kerns</surname>, <given-names>E. H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fan K."><surname>Fan</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="McConnell O. J."><surname>McConnell</surname>, <given-names>O. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Carter G. T."><surname>Carter</surname>, <given-names>G. T.</given-names></string-name>, <article-title hwp:id="article-title-42">High throughput artificial membrane permeability assay for blood-brain barrier</article-title>. <source hwp:id="source-41">Eur J Med Chem</source> <year>2003</year>, <volume>38</volume> (<issue>3</issue>), <fpage>223</fpage>–<lpage>32</lpage>.</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Connelly C. M."><surname>Connelly</surname>, <given-names>C. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Moon M. H."><surname>Moon</surname>, <given-names>M. H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schneekloth J. S. Jr"><surname>Schneekloth</surname>, <given-names>J. S.</given-names>, <suffix>Jr</suffix></string-name>., <article-title hwp:id="article-title-43">The Emerging Role of RNA as a Therapeutic Target for Small Molecules</article-title>. <source hwp:id="source-42">Cell Chem Biol</source> <year>2016</year>, <volume>23</volume> (<issue>9</issue>), <fpage>1077</fpage>–<lpage>1090</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Tok J. B. H."><surname>Tok</surname>, <given-names>J. B. H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Rando R. R."><surname>Rando</surname>, <given-names>R. R.</given-names></string-name>, <article-title hwp:id="article-title-44">Simple aminols as aminoglycoside surrogates</article-title>. <source hwp:id="source-43">Journal of the American Chemical Society</source> <year>1998</year>, <volume>120</volume> (<issue>32</issue>), <fpage>8279</fpage>–<lpage>8280</lpage>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="other" citation-type="journal" ref:id="389148v1.44" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Blount K. F."><surname>Blount</surname>, <given-names>K. F.</given-names></string-name> <article-title hwp:id="article-title-45">Methods for treating or inhibiting infection by clostridium difficile</article-title>. <year>2013</year>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Howe J. A."><surname>Howe</surname>, <given-names>J. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Xiao L."><surname>Xiao</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fischmann T. O."><surname>Fischmann</surname>, <given-names>T. O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang H."><surname>Wang</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Tang H."><surname>Tang</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Villafania A."><surname>Villafania</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zhang R."><surname>Zhang</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Barbieri C. M."><surname>Barbieri</surname>, <given-names>C. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Roemer T."><surname>Roemer</surname>, <given-names>T.</given-names></string-name>, <article-title hwp:id="article-title-46">Atomic resolution mechanistic studies of ribocil: A highly selective unnatural ligand mimic of the E. coli FMN riboswitch</article-title>. <source hwp:id="source-44">RNA Biol</source> <year>2016</year>, <volume>13</volume> (<issue>10</issue>), <fpage>946</fpage>–<lpage>954</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Hermann T."><surname>Hermann</surname>, <given-names>T.</given-names></string-name>, <article-title hwp:id="article-title-47">Drugs targeting the ribosome</article-title>. <source hwp:id="source-45">Curr Opin Struct Biol</source> <year>2005</year>, <volume>15</volume> (<issue>3</issue>), <fpage>355</fpage>–<lpage>66</lpage>.</citation></ref><ref id="c47" hwp:id="ref-47"><label>47.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Francois B."><surname>Francois</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Russell R. J."><surname>Russell</surname>, <given-names>R. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Murray J. B."><surname>Murray</surname>, <given-names>J. B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Aboul-ela F."><surname>Aboul-ela</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Masquida B."><surname>Masquida</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Vicens Q."><surname>Vicens</surname>, <given-names>Q.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Westhof E."><surname>Westhof</surname>, <given-names>E.</given-names></string-name>, <article-title hwp:id="article-title-48">Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding</article-title>. <source hwp:id="source-46">Nucleic Acids Res</source> <year>2005</year>, <volume>33</volume> (<issue>17</issue>), <fpage>5677</fpage>–<lpage>90</lpage>.</citation></ref><ref id="c48" hwp:id="ref-48"><label>48.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.48" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Maraki S."><surname>Maraki</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Samonis G."><surname>Samonis</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Karageorgopoulos D. E."><surname>Karageorgopoulos</surname>, <given-names>D. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mavros M. N."><surname>Mavros</surname>, <given-names>M. N.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kofteridis D."><surname>Kofteridis</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Falagas M. E."><surname>Falagas</surname>, <given-names>M. E.</given-names></string-name>, <article-title hwp:id="article-title-49">In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece</article-title>. <source hwp:id="source-47">Antimicrob Agents Chemother</source> <year>2012</year>, <volume>56</volume> (<issue>6</issue>), <fpage>3067</fpage>–<lpage>73</lpage>.</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label>49.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.49" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-49"><string-name name-style="western" hwp:sortable="Armstrong E. S."><surname>Armstrong</surname>, <given-names>E. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Miller G. H."><surname>Miller</surname>, <given-names>G. H.</given-names></string-name>, <article-title hwp:id="article-title-50">Combating evolution with intelligent design: the neoglycoside ACHN-490</article-title>. <source hwp:id="source-48">Curr Opin Microbiol</source> <year>2010</year>, <volume>13</volume> (<issue>5</issue>), <fpage>565</fpage>–<lpage>73</lpage>.</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1 xref-ref-50-2 xref-ref-50-3"><label>50.</label><citation publication-type="other" citation-type="journal" ref:id="389148v1.50" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Rizvi N. F."><surname>Rizvi</surname>, <given-names>N. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Howe J. A."><surname>Howe</surname>, <given-names>J. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nahvi A."><surname>Nahvi</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Klein D. J."><surname>Klein</surname>, <given-names>D. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Fischmann T. O."><surname>Fischmann</surname>, <given-names>T. O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Kim H.-y."><surname>Kim</surname>, <given-names>H.-y.</given-names></string-name>; <string-name name-style="western" hwp:sortable="McCoy M. A."><surname>McCoy</surname>, <given-names>M. A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Walker S. S."><surname>Walker</surname>, <given-names>S. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Hruza A."><surname>Hruza</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Richards M. P."><surname>Richards</surname>, <given-names>M. P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Chamberlin C."><surname>Chamberlin</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Saradjian P."><surname>Saradjian</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Butko M. T."><surname>Butko</surname>, <given-names>M. T.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mercado G."><surname>Mercado</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Burchard J."><surname>Burchard</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Strickland C."><surname>Strickland</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Dandliker P. J."><surname>Dandliker</surname>, <given-names>P. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Smith G. F."><surname>Smith</surname>, <given-names>G. F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nickbarg E. B."><surname>Nickbarg</surname>, <given-names>E. B.</given-names></string-name>, <article-title hwp:id="article-title-51">Discovery of selective RNA-binding small molecules by affinity-selection mass spectrometry</article-title>. <source hwp:id="source-49">ACS Chemical Biology</source> <year>2018</year>.</citation></ref><ref id="c51" hwp:id="ref-51" hwp:rev-id="xref-ref-51-1"><label>51.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.51" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-51"><string-name name-style="western" hwp:sortable="Jarvis T. C."><surname>Jarvis</surname>, <given-names>T. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Davies D. R."><surname>Davies</surname>, <given-names>D. R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Hisaminato A."><surname>Hisaminato</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Resnicow D. I."><surname>Resnicow</surname>, <given-names>D. I.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Gupta S."><surname>Gupta</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Waugh S. M."><surname>Waugh</surname>, <given-names>S. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nagabukuro A."><surname>Nagabukuro</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wadatsu T."><surname>Wadatsu</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Hishigaki H."><surname>Hishigaki</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Gawande B."><surname>Gawande</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Zhang C."><surname>Zhang</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wolk S. K."><surname>Wolk</surname>, <given-names>S. K.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Mayfield W. S."><surname>Mayfield</surname>, <given-names>W. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Nakaishi Y."><surname>Nakaishi</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Burgin A. B."><surname>Burgin</surname>, <given-names>A. B.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Stewart L. J."><surname>Stewart</surname>, <given-names>L. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Edwards T. E."><surname>Edwards</surname>, <given-names>T. E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Gelinas A. D."><surname>Gelinas</surname>, <given-names>A. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Schneider D. J."><surname>Schneider</surname>, <given-names>D. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Janjic N."><surname>Janjic</surname>, <given-names>N.</given-names></string-name>, <article-title hwp:id="article-title-52">Non-helical DNA Triplex Forms a Unique Aptamer Scaffold for High Affinity Recognition of Nerve Growth Factor</article-title>. <source hwp:id="source-50">Structure</source> <year>2015</year>, <volume>23</volume> (<issue>7</issue>), <fpage>1293</fpage>–<lpage>304</lpage>.</citation></ref><ref id="c52" hwp:id="ref-52"><label>52.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.52" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-52"><string-name name-style="western" hwp:sortable="Cottarel G."><surname>Cottarel</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wierzbowski J."><surname>Wierzbowski</surname>, <given-names>J.</given-names></string-name>, <article-title hwp:id="article-title-53">Combination drugs, an emerging option for antibacterial therapy</article-title>. <source hwp:id="source-51">Trends Biotechnol</source> <year>2007</year>, <volume>25</volume> (<issue>12</issue>), <fpage>547</fpage>–<lpage>55</lpage>.</citation></ref><ref id="c53" hwp:id="ref-53"><label>53.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.53" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-53"><string-name name-style="western" hwp:sortable="Fischbach M. A."><surname>Fischbach</surname>, <given-names>M. A.</given-names></string-name>, <article-title hwp:id="article-title-54">Combination therapies for combating antimicrobial resistance</article-title>. <source hwp:id="source-52">Curr Opin Microbiol</source> <year>2011</year>, <volume>14</volume> (<issue>5</issue>), <fpage>519</fpage>–<lpage>23</lpage>.</citation></ref><ref id="c54" hwp:id="ref-54" hwp:rev-id="xref-ref-54-1"><label>54.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.54" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-54"><string-name name-style="western" hwp:sortable="Landick R."><surname>Landick</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Wang D."><surname>Wang</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Chan C. L."><surname>Chan</surname>, <given-names>C. L.</given-names></string-name>, <article-title hwp:id="article-title-55">Quantitative analysis of transcriptional pausing by <italic toggle="yes">Escherichi coli</italic> RNA polymerase: His leader pause site as a paradigm</article-title>. <source hwp:id="source-53">Methods in Enzymology</source> <year>1996</year>, <volume>274</volume>, <fpage>334</fpage>–<lpage>353</lpage>.</citation></ref><ref id="c55" hwp:id="ref-55" hwp:rev-id="xref-ref-55-1 xref-ref-55-2"><label>55.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.55" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-55"><string-name name-style="western" hwp:sortable="Das R."><surname>Das</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Laederach A."><surname>Laederach</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Pearlman S. M."><surname>Pearlman</surname>, <given-names>S. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Herschlag D."><surname>Herschlag</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Altman R. B."><surname>Altman</surname>, <given-names>R. B.</given-names></string-name>, <article-title hwp:id="article-title-56">SAFA: semiautomated footprinting analysis software for high-throughput quantification of nucleic acid footprinting experiments</article-title>. <source hwp:id="source-54">RNA</source> <year>2005</year>, <volume>11</volume> (<issue>3</issue>), <fpage>344</fpage>–<lpage>54</lpage>.</citation></ref><ref id="c56" hwp:id="ref-56" hwp:rev-id="xref-ref-56-1 xref-ref-56-2"><label>56.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.56" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-56"><string-name name-style="western" hwp:sortable="Laederach A."><surname>Laederach</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Das R."><surname>Das</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Vicens Q."><surname>Vicens</surname>, <given-names>Q.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Pearlman S. M."><surname>Pearlman</surname>, <given-names>S. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Brenowitz M."><surname>Brenowitz</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Herschlag D."><surname>Herschlag</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Altman R. B."><surname>Altman</surname>, <given-names>R. B.</given-names></string-name>, <article-title hwp:id="article-title-57">Semiautomated and rapid quantification of nucleic acid footprinting and structure mapping experiments</article-title>. <source hwp:id="source-55">Nat Protoc</source> <year>2008</year>, <volume>3</volume> (<issue>9</issue>), <fpage>1395</fpage>–<lpage>401</lpage>.</citation></ref><ref id="c57" hwp:id="ref-57" hwp:rev-id="xref-ref-57-1"><label>57.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.57" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-57"><string-name name-style="western" hwp:sortable="Robinson H."><surname>Robinson</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Soares A. S."><surname>Soares</surname>, <given-names>A. S.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Becker M."><surname>Becker</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sweet R."><surname>Sweet</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Heroux A."><surname>Heroux</surname>, <given-names>A.</given-names></string-name>, <article-title hwp:id="article-title-58">Mail-in crystallography program at Brookhaven National Laboratory’s National Synchrotron Light Source</article-title>. <source hwp:id="source-56">Acta Cryst</source> <year>2006</year>, <volume>D62</volume> (<issue>Pt 11</issue>), <fpage>1336</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c58" hwp:id="ref-58" hwp:rev-id="xref-ref-58-1"><label>58.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.58" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-58"><string-name name-style="western" hwp:sortable="Vonrhein C."><surname>Vonrhein</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Flensburg C."><surname>Flensburg</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Keller P."><surname>Keller</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Sharff A."><surname>Sharff</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Smart O."><surname>Smart</surname>, <given-names>O.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Paciorek W."><surname>Paciorek</surname>, <given-names>W.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Womack T."><surname>Womack</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bricogne G."><surname>Bricogne</surname>, <given-names>G.</given-names></string-name>, <article-title hwp:id="article-title-59">Data processing and analysis with the autoPROC toolbox</article-title>. <source hwp:id="source-57">Acta Crystallogr D Biol Crystallogr</source> <year>2011</year>, <volume>67</volume> (<issue>Pt 4</issue>), <fpage>293</fpage>–<lpage>302</lpage>.</citation></ref><ref id="c59" hwp:id="ref-59" hwp:rev-id="xref-ref-59-1"><label>59.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.59" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-59"><string-name name-style="western" hwp:sortable="Otwinowski Z."><surname>Otwinowski</surname>, <given-names>Z.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Minor W."><surname>Minor</surname>, <given-names>W.</given-names></string-name>, <article-title hwp:id="article-title-60">Processing of X-ray diffraction data collected in oscillation mode</article-title>. <source hwp:id="source-58">Methods Enzymol</source> <year>1997</year>, <volume>276</volume>, <fpage>307</fpage>–<lpage>26</lpage>.</citation></ref><ref id="c60" hwp:id="ref-60" hwp:rev-id="xref-ref-60-1"><label>60.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.60" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-60"><string-name name-style="western" hwp:sortable="McCoy A. J."><surname>McCoy</surname>, <given-names>A. J.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Grosse-Kunstleve R. W."><surname>Grosse-Kunstleve</surname>, <given-names>R. W.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Adams P. D."><surname>Adams</surname>, <given-names>P. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Winn M. D."><surname>Winn</surname>, <given-names>M. D.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Storoni L. C."><surname>Storoni</surname>, <given-names>L. C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Read R. J."><surname>Read</surname>, <given-names>R. J.</given-names></string-name>, <article-title hwp:id="article-title-61">Phaser crystallographic software</article-title>. <source hwp:id="source-59">J Appl Crystallogr</source> <year>2007</year>, <volume>40</volume> (<issue>Pt 4</issue>), <fpage>658</fpage>–<lpage>674</lpage>.</citation></ref><ref id="c61" hwp:id="ref-61" hwp:rev-id="xref-ref-61-1"><label>61.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.61" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-61"><string-name name-style="western" hwp:sortable="Blanc E."><surname>Blanc</surname>, <given-names>E.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Roversi P."><surname>Roversi</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Vonrhein C."><surname>Vonrhein</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Flensburg C."><surname>Flensburg</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Lea S. M."><surname>Lea</surname>, <given-names>S. M.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bricogne G."><surname>Bricogne</surname>, <given-names>G.</given-names></string-name>, <article-title hwp:id="article-title-62">Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT</article-title>. <source hwp:id="source-60">Acta Crystallogr D Biol Crystallogr</source> <year>2004</year>, <volume>60</volume> (<issue>Pt 12 Pt 1</issue>), <fpage>2210</fpage>–<lpage>21</lpage>.</citation></ref><ref id="c62" hwp:id="ref-62" hwp:rev-id="xref-ref-62-1"><label>62.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.62" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-62"><string-name name-style="western" hwp:sortable="Auffinger P."><surname>Auffinger</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Bielecki L."><surname>Bielecki</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Westhof E."><surname>Westhof</surname>, <given-names>E.</given-names></string-name>, <article-title hwp:id="article-title-63">Anion binding to nucleic acids</article-title>. <source hwp:id="source-61">Structure</source> <year>2004</year>, <volume>12</volume> (<issue>3</issue>), <fpage>379</fpage>–<lpage>88</lpage>.</citation></ref><ref id="c63" hwp:id="ref-63"><label>63.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.63" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-63"><string-name name-style="western" hwp:sortable="Auffinger P."><surname>Auffinger</surname>, <given-names>P.</given-names></string-name>; <string-name name-style="western" hwp:sortable="D’Ascenzo L."><surname>D’Ascenzo</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Ennifar E."><surname>Ennifar</surname>, <given-names>E.</given-names></string-name>, <article-title hwp:id="article-title-64">Sodium and Potassium Interactions with Nucleic Acids</article-title>. <source hwp:id="source-62">Met Ions Life Sci</source> <year>2016</year>, <volume>16</volume>, <fpage>167</fpage>–<lpage>201</lpage>.</citation></ref><ref id="c64" hwp:id="ref-64"><label>64.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.64" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-64"><string-name name-style="western" hwp:sortable="D’Ascenzo L."><surname>D’Ascenzo</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Auffinger P."><surname>Auffinger</surname>, <given-names>P.</given-names></string-name>, <article-title hwp:id="article-title-65">Anions in Nucleic Acid Crystallography</article-title>. <source hwp:id="source-63">Methods Mol Biol</source> <year>2016</year>, <volume>1320</volume>, <fpage>337</fpage>–<lpage>51</lpage>.</citation></ref><ref id="c65" hwp:id="ref-65" hwp:rev-id="xref-ref-65-1"><label>65.</label><citation publication-type="journal" citation-type="journal" ref:id="389148v1.65" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-65"><string-name name-style="western" hwp:sortable="Leonarski F."><surname>Leonarski</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western" hwp:sortable="D’Ascenzo L."><surname>D’Ascenzo</surname>, <given-names>L.</given-names></string-name>; <string-name name-style="western" hwp:sortable="Auffinger P."><surname>Auffinger</surname>, <given-names>P.</given-names></string-name>, <article-title hwp:id="article-title-66">Mg2+ ions: do they bind to nucleobase nitrogens?</article-title> <source hwp:id="source-64">Nucleic Acids Res</source> <year>2017</year>, <volume>45</volume> (<issue>2</issue>), <fpage>987</fpage>–<lpage>1004</lpage>.</citation></ref></ref-list><sec sec-type="display-objects" hwp:id="sec-20"><title hwp:id="title-30">TABLES</title><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389148v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1.</label><caption hwp:id="caption-8"><p hwp:id="p-45">Data collection and refinement statistics.</p></caption><graphic xlink:href="389148_tbl1" position="float" orientation="portrait" hwp:id="graphic-8"/></table-wrap></sec></back></article>
